<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Carboplatin: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Carboplatin: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Carboplatin: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9202" href="/d/html/9202.html" rel="external">see "Carboplatin: Drug information"</a> and <a class="drug drug_patient" data-topicid="11756" href="/d/html/11756.html" rel="external">see "Carboplatin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708661"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Experienced physician:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Carboplatin should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate treatment facilities are readily available.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Bone marrow suppression: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Bone marrow suppression is dose related and may be severe, resulting in infection or bleeding. Anemia may be cumulative and may require transfusion support. </p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Vomiting:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Vomiting is a frequent drug-related side effect.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Anaphylactic-like reactions to carboplatin have been reported and may occur within minutes of carboplatin administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F54135155"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Paraplatin</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1045745"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antineoplastic Agent, Alkylating Agent</span>;</li>
<li>
<span class="list-set-name">Antineoplastic Agent, Platinum Analog</span></li></ul></div>
<div class="block dop drugH1Div" id="F146217"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing and frequency may vary by protocol and/or treatment phase; refer to specific protocol. In pediatric patients, dosing may be based on either BSA (mg/m<sup>2</sup>), weight (mg/<b>kg</b>), or a modified Calvert formula calculation (mg); use extra precaution to verify dosing parameters and units of GFR/estimated CrCl during calculations, as errors can lead to significant over/under dosing. Some protocols suggest weight or age cut-offs for weight-based (mg/kg) dosing; refer to specific protocol. Carboplatin is associated with a high emetic potential in pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30729654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30729654'])">Ref</a></span>); antiemetics are recommended to prevent nausea and vomiting.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Calvert Formula, modified:</b> Limited data available; multiple formulas have been used; formula may be protocol-specific (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14528109']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14528109'])">Ref</a></span>): Some protocols may calculate pediatric carboplatin doses using one of the following modified Calvert formulas:</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption>
<b>Modified Calvert Formulas</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><tbody>
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;margin-top:2em;text-align:left;">Target AUC: Protocol specific dependent upon indication; value presented in terms of mg/mL and minute units (eg, mg/mL/minute or mg/mL•minute are frequently reported).</p>
<p style="text-indent:0em;margin-top:2em;text-align:left;">
<b>Note:</b> Ensure appropriate GFR value<sup>A</sup> is used for calculation and resulting carboplatin dose (mg or mg/m<sup>2</sup>) units.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Newell formula</p>
<p style="text-indent:0em;">(Newell 1993)</p></td>
<td align="left">
<p style="text-indent:0em;">
<b>Total dose (mg) =</b> Target AUC x [uncorrected or raw GFR (mL/minute) + (0.36 x kg body weight)]</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Mann/Pein formula</p>
<p style="text-indent:0em;">(Mann 1998; Mann 2000; Pein 1998)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Total dose (mg)</b> = Target AUC x [uncorrected or raw GFR (mL/minute) + (15 x BSA(m<sup>2</sup>))]</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Marina/St. Jude formula<sup>B</sup></p>
<p style="text-indent:0em;">(Allen 2010; Marina 1993)</p></td>
<td align="center">
<p style="text-indent:-2em;margin-left:2em;text-align:left;">
<b>Dose (mg/m<sup>2</sup>)</b> = Target AUC x [(0.93 x corrected GFR normalized to patient’s BSA (mL/minute/m<sup>2 </sup>
<sup></sup>)) + 15]</p></td></tr>
<tr>
<td align="center" colspan="2">
<p style="text-indent:-2em;margin-left:2em;text-align:left;">
<sup>A</sup>GFR definitions:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:left;">Raw GFR = uncorrected GFR = mL/minute</p>
<p style="text-indent:-2em;margin-left:4em;text-align:left;">Normalized GFR = corrected GFR = mL/minute/1.73 m<sup>2</sup></p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;text-align:left;">
<sup>B</sup>Marina/St. Jude formula: Uses a corrected GFR normalized to patient’s BSA (mL/minute/m<sup>2</sup>); converting GFR to this may be done as follows:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:left;">Corrected GFR (mL/minute/1.73 m<sup>2</sup>)/1.73 = GFR (mL/minute/m<sup>2</sup>)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:left;">Uncorrected GFR (mL/minute)/patient’s BSA = GFR (mL/minute/m<sup>2</sup>)</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Calvert formula was based on using chromic edetate (51Cr-EDTA) plasma clearance to establish GFR. This or 99mTc- DTPA nuclear medicine GFR study is preferred over estimating CrCl per Schwartz equation as CrCl theoretically exceeds measured GFR by &gt;12% in subjects with normal renal function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20486170']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20486170'])">Ref</a></span>) (see Warnings/Precautions for additional information).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="19842fc6-0cc3-4e74-8924-8527229d5fa2">Hematopoietic stem cell transplant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic stem cell transplant (HSCT):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cohen 2015:</i> Consolidation with myeloablative chemotherapy: Infants ≥6 months and Children ≤3 years: IV: 17 mg/<b>kg</b> over 2 hours on days 0 and 1 of a 21-day cycle in combination with thiotepa for 3 cycles.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Gilheeney 2010, Kushner 2001:</i> Myeloablative: Children and Adolescents: IV: ~500 mg/m<sup>2</sup> over 4 hours for 3 doses on days -5 to -3; dosing utilized Calvert formula with a target AUC=7 in combination regimen with thiotepa and topotecan.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Spreafico 2008:</i> Consolidation after reinduction chemo (relapsed Wilms Tumor): Children &lt;12 years: IV: 200 mg/m<sup>2</sup> for 4 doses on days -6 to -3 in combination with melphalan and etoposide.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="12ce2012-e953-4a34-91ef-9d721259c005">Glioma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Glioma:</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9126887']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9126887'])">Ref</a></span>): Infants ≥3 months, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Induction: IV: 175 mg/m<sup>2</sup> once weekly for 4 weeks every 6 weeks (2-week recovery period between courses) in combination with vincristine for 2 cycles</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance: IV: 175 mg/m<sup>2</sup> weekly for 4 weeks, with a 3-week recovery period between courses in combination with vincristine for ≤12 cycles</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="69395a97-ddc6-417a-98a0-8e6b528700fc">Neuroblastoma, localized and unresectable</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroblastoma, localized and unresectable:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: IV: 6.6 mg/<b>kg</b> on days 1, 2, and 3 in combinations with etoposide for 2 cycles (CE regimen), followed by cyclophosphamide, doxorubicin, and vincristine (CAdO regimen) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11464897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11464897'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;10 kg: IV: 100 to 140 mg/m<sup>2</sup>/day on days 1, 2, and 3 every 21 days in combination with etoposide for 2 cycles (CE regimen), followed by cyclophosphamide, doxorubicin, and vincristine (CAdO regimen) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9649151']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9649151'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥10 kg and Adolescents: IV: 200 mg/m<sup>2</sup>/day on days 1, 2, and 3 every 21 days in combination with etoposide for 2 cycles (CE regimen), followed by cyclophosphamide, doxorubicin, and vincristine (CAdO regimen) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9649151']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9649151'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="31e6cee0-3b53-4b61-b4ee-8c7e85d9d0bb">Retinoblastoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Retinoblastoma:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Rodriguez-Galindo 2003:</i> Infants and Children:</p>
<p style="text-indent:-2em;margin-left:6em;">GFR ≥50 mL/minute/m<sup>2</sup>: IV: 560 mg/m<sup>2</sup> in combination with vincristine every 21 days for 8 cycles</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &lt;50 mL/minute/m<sup>2</sup>: IV: Dosing utilized modified Calvert formula with a target AUC=6.5 in combination regimen with vincristine every 21 days for 8 cycles</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Friedman 2000: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children ≤3 years: IV: 18.6 mg/<b>kg</b> on day 0 every 28 days in combination with etoposide and vincristine for 6 cycles (VEC regimen)</p>
<p style="text-indent:-2em;margin-left:6em;">Children &gt;3 years: IV: 560 mg/m<sup>2</sup> on day 0 every 28 days in combination with etoposide and vincristine for 6 cycles (VEC regimen)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="46835e52-b183-4843-a532-a3ddb9c57c2e">Sarcomas; Ewing sarcoma, osteosarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sarcomas; Ewing sarcoma, osteosarcoma:</b> Children and Adolescents: IV: 400 mg/m<sup>2</sup>/day for 2 days every 21 days in combination with ifosfamide and etoposide (ICE regimen) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15503297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15503297'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="33321132-9b42-4496-ab22-eee8b2d8f8c5">Wilms tumor, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Wilms tumor, relapsed/refractory: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Abu-Ghosh 2002; Daw 2009:</i> Children and Adolescents: IV: 400 mg/m<sup>2</sup>/day for 2 days or modified Calvert using Marina/St. Jude formula with a target AUC=6 for 1 day in combination with ifosfamide and etoposide every 21 days (ICE regimen)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i> Spreafico 2008: </i>Reinduction prior to autologous stem cell rescue: Children &lt;12 years: IV: 600 mg/m<sup>2</sup> for 1 dose in combination with ifosfamide and etoposide</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b> The presented dosing adjustments are based on experience in adult patients; specific recommendations for pediatric patients are limited. Refer to specific protocol for management in pediatric patients if available.</p>
<p style="text-indent:-2em;margin-left:4em;">Adult: Post-treatment nadir: Platelets &lt;50,000 cells/mm<sup>3</sup> or ANC &lt;500 cells/mm<sup>3</sup>: Administer 75% of dose</p></div>
<div class="block dorp drugH1Div" id="F51083907"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: The following dosage adjustments have been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary</p>
<p style="text-indent:-2em;margin-left:6em;">GFR ≤50 mL/minute/1.73 m<sup>2</sup>: Use modified Calvert formula (see protocol for specific details) incorporating patient's GFR</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous renal replacement therapy (CRRT): Use modified Calvert formula (see protocol for specific details) incorporating GFR of 33 mL/minute</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis, peritoneal dialysis: Use modified Calvert formula (see protocol for specific details) incorporating GFR &lt;10 mL/minute</p></div>
<div class="block dohp drugH1Div" id="F51083908"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, carboplatin undergoes minimal hepatic metabolism; dosage adjustment may not be needed.</p></div>
<div class="block doa drugH1Div" id="F146192"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9202" href="/d/html/9202.html" rel="external">see "Carboplatin: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Doses for adults are commonly calculated by the Target AUC using the Calvert formula, where <b>Total dose (mg) = Target AUC × (GFR + 25)</b>. If estimating GFR for use in the Calvert formula, the FDA recommends that clinicians consider capping estimated GFR at a maximum of 125 mL/minute to avoid potential toxicity. Measured CrCl or GFR is preferred, especially when the intent is curative or if the patient is at extremes of body composition (size or muscle mass) or has an eGFR ≤45 mL/minute/1.73 m<sup>2</sup> or &gt;125 mL/minute/1.73 m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26351333']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26351333'])">Ref</a></span>). Antiemetics may be recommended to prevent nausea and vomiting; carboplatin is associated with a moderate or high emetic potential (dose/AUC dependent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d5660db6-cd1b-4002-99d3-1478f87fd429">Anal cancer, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anal cancer, advanced (off-label use):</b>
<b>IV:</b> Target AUC 5 on day 1 every 4 weeks (in combination with paclitaxel) for 6 cycles or until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32530769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32530769'])">Ref</a></span>) <b>or</b> Target AUC 5 or 6 every 3 weeks (in combination with paclitaxel) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25012155']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25012155'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3810c766-bd22-4b38-a74f-83d570ec742e">Bladder cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bladder cancer (off-label use):</b>
<b>IV:</b> Target AUC 5 on day 1 every 3 weeks (in combination with gemcitabine) for 6 cycles unless disease progression or unacceptable toxicity occurred; may continue beyond 6 cycles if clinical benefit (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16342065']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16342065'])">Ref</a></span>) <b>or </b>Target AUC 4.5 on day 1 every 3 weeks (in combination with gemcitabine) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22162575']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22162575'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">First-line carboplatin (in combination with gemcitabine; doses not specified) for 4 to 6 cycles, followed by maintenance avelumab + best supportive care (BSC) significantly prolonged overall survival (compared to BSC alone) in unresectable locally advanced or metastatic urothelial cancer that had not progressed following the first-line platinum-based chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32945632']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32945632'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4b32fca0-7c36-4eb5-bbdb-f083eb09a582">Breast cancer, advanced or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, advanced or metastatic (off-label use):</b>
<b>IV:</b> Target AUC 6 on day 2 every 3 weeks (in combination with trastuzumab and paclitaxel) for at least 6 cycles, followed by trastuzumab monotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16782917']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16782917'])">Ref</a></span>) <b>or</b> Target AUC 6 on day 1 or day 2 every 3 weeks (in combination with trastuzumab and docetaxel) for 6 or 8 cycles, followed by trastuzumab monotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15150304','lexi-content-ref-21115860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15150304','lexi-content-ref-21115860'])">Ref</a></span>) <b>or </b>Target AUC 6 every 3 weeks (in combination with paclitaxel) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10618614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10618614'])">Ref</a></span>) <b>or</b> Target AUC 2 on days 1, 8, and 15 every 4 weeks (in combination with weekly paclitaxel) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12228205']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12228205'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Triple-negative advanced or metastatic breast cancer:</i>
<b>IV:</b> Target AUC 2 on days 1 and 8 every 3 weeks (in combination with gemcitabine and pembrolizumab); refer to protocol for details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33278935']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33278935'])">Ref</a></span>) <b>or </b>Target AUC 2 on days 1 and 8 every 3 weeks (in combination with paclitaxel [protein bound]) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29878040']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29878040'])">Ref</a></span>) <b>or</b> Target AUC 6 (as a single agent) every 3 weeks until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25847936']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25847936'])">Ref</a></span>) <b>or</b> Target AUC 6 (as a single agent) every 3 weeks for 6 cycles; if responding to and tolerating treatment, may receive an additional 2 cycles per local policy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29713086']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29713086'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8d89c9d3-33a6-4071-afe7-addef48a154f">Breast cancer, neoadjuvant/adjuvant therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, neoadjuvant/adjuvant therapy (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Triple-negative breast cancer (neoadjuvant): </i>
<b>IV:</b> Target AUC 6 on day 1 every 3 weeks (in combination with weekly paclitaxel) for 4 cycles, followed by 4 cycles of doxorubicin and cyclophosphamide, followed by surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29501363']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29501363'])">Ref</a></span>) <b>or</b> Target AUC 6 every 3 weeks (in combination with docetaxel and WBC growth factor support) for 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27301700','lexi-content-ref-30061361']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27301700','lexi-content-ref-30061361'])">Ref</a></span>) <b>or</b>
<i>either</i> Target AUC 5 every 3 weeks <i>or </i>Target AUC 1.5 on days 1, 8, and 15 every 3 weeks (in combination with paclitaxel and pembrolizumab [first neoadjuvant treatment]) for 4 cycles, followed by second neoadjuvant treatment of pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32101663','lexi-content-ref-35139274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32101663','lexi-content-ref-35139274'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>TCHP regimen (neoadjuvant; HER2-positive): </i>
<b>IV:</b> Target AUC 6 every 3 weeks (in combination with trastuzumab, pertuzumab, and docetaxel) for 6 cycles, followed by surgery along with trastuzumab monotherapy to complete 1 year of trastuzumab therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23704196']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23704196'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>TCH regimen (adjuvant; HER2-positive):</i>
<b>IV:</b> Target AUC 6 every 3 weeks (in combination with docetaxel and trastuzumab) for 6 cycles, followed by trastuzumab monotherapy to complete 52 weeks of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21991949']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21991949'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="abc28755-296d-44c6-8865-b968961e4811">Cervical cancer, recurrent or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cervical cancer, recurrent or metastatic (off-label use):</b>
<b>IV:</b> Target AUC 5 every 3 weeks (in combination with paclitaxel) for 6 to 9 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19509587']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19509587'])">Ref</a></span>) <b>or</b> Target AUC 5 to 6 on day 1 every 4 weeks (in combination with paclitaxel) for 6 to 9 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15904950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15904950'])">Ref</a></span>) <b>or</b> 400 mg/m<sup>2</sup> on day 1 every 28 days (as a single agent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2258080']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2258080'])">Ref</a></span>) <b>or </b>Target AUC 5 on day 1 every 3 weeks on day 1 (in combination with paclitaxel) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25732161']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25732161'])">Ref</a></span>) <b>or</b> Target AUC 5 on day 1 every 3 weeks (in combination with paclitaxel and bevacizumab) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32763109']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32763109'])">Ref</a></span>) <b>or</b> Target AUC 5 on day 1 every 3 weeks (in combination with pembrolizumab and paclitaxel [conventional] ± bevacizumab) for 6 cycles; patients could continue chemotherapy beyond 6 cycles if experiencing clinical benefit without unacceptable toxicity; refer to protocol for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34534429']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34534429'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7e78ab22-88ee-4724-83ea-ceee9790b47e">Endometrial cancer, advanced or recurrent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometrial cancer, advanced or recurrent (off-label use):</b>
<b>IV:</b> Target AUC 6 on day 1 every 3 weeks (in combination with paclitaxel) for up to 7 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33078978']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33078978'])">Ref</a></span>) <b>or </b>Target AUC 5 on day 1 every 3 weeks (in combination with paclitaxel and dostarlimab) for 6 cycles, followed by dostarlimab monotherapy until disease progression, unacceptable toxicity, or for up to 3 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36972026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36972026'])">Ref</a></span>) <b>or </b>Target AUC 5 every 3 weeks (in combination with paclitaxel) for 6 to 9 cycles or until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18299146']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18299146'])">Ref</a></span>) <b>or</b> Target AUC 2 on days 1, 8, and 15 every 28 days (in combination with paclitaxel) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17380438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17380438'])">Ref</a></span>) <b>or</b> Target AUC 5 on day 1 every 3 weeks (in combination with paclitaxel and bevacizumab) for 6 to 8 cycles, followed by bevacizumab maintenance; refer to protocol for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31677820']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31677820'])">Ref</a></span>) <b>or</b>
<i>(for HER2+ uterine serous cancer)</i> Target AUC 5 every 3 weeks (in combination with paclitaxel and trastuzumab) for ~6 cycles, followed by trastuzumab maintenance therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29584549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29584549'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e50dc227-3f50-48ae-aba5-898bd2fb9c33">Esophageal cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Esophageal cancer (off-label use): IV:</b> Target AUC 2 once weekly for 5 weeks (in combination with paclitaxel and radiation therapy) prior to surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22646630','lexi-content-ref-16670722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22646630','lexi-content-ref-16670722'])">Ref</a></span>) <b>or</b> Target AUC 5 every 3 weeks (in combination with paclitaxel) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15151955']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15151955'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0941e1ee-82d0-48a1-a4ca-aa05a3115959">Gastric cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastric cancer (off-label use): IV:</b> Target AUC 2 once weekly for 5 weeks (in combination with paclitaxel and concurrent radiation) prior to surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22646630']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22646630'])">Ref</a></span>) <b>or</b> Target AUC 5 to 6 every 3 weeks (in combination with paclitaxel) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12576922']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12576922'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cb13a230-c3e9-4d98-8e1c-329ed6d201bb">Gestational trophoblastic neoplasia, high-risk, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gestational trophoblastic neoplasia, high-risk, refractory (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Carboplatin/paclitaxel regimen:</i>
<b>IV:</b> Target AUC 6 once every 3 weeks (in combination with paclitaxel); continue for 2 treatment cycles after an undetectable hCG level (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26401644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26401644'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>ICE regimen: </i>
<b>IV: </b>Target AUC 4 on day 1 every 3 weeks (in combination with ifosfamide, mesna, etoposide and pegfilgrastim or filgrastim); continue for at least 2 treatment cycles after a normal hCG level (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20626175','lexi-content-ref-22696816']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20626175','lexi-content-ref-22696816'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="01cd0f58-ce35-4245-b8e0-406d23a85003">Head and neck cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Head and neck cancer (off-label use):</b>
<b>IV:</b> Target AUC 5 on day 1 every 3 weeks (in combination with cetuximab) until disease progression or unacceptable toxicity or a maximum of 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15809453']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15809453'])">Ref</a></span>) <b>or</b> Target AUC 5 on day 1 every 3 weeks (in combination with cetuximab and fluorouracil) for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18784101']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18784101'])">Ref</a></span>) <b>or</b> 300 mg/m<sup>2</sup> on day 1 every 4 weeks (in combination with fluorouracil) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1634913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1634913'])">Ref</a></span>) <b>or</b> Target AUC 6 on day 1 every 3 weeks (in combination with paclitaxel) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11745288']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11745288'])">Ref</a></span>) <b>or </b>Target AUC 1.5 weekly for 7 weeks (in combination with radiation, following 3 cycles of docetaxel, cisplatin, and fluorouracil [TPF] induction therapy [begin carboplatin/radiation therapy 3 to 8 weeks after the start of TPF cycle 3]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23414589','lexi-content-ref-17960013']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23414589','lexi-content-ref-17960013'])">Ref</a></span>) <b>or</b> Target AUC 5 every 3 weeks (in combination with fluorouracil and pembrolizumab) for 6 cycles, followed by up to 24 months of pembrolizumab monotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31679945']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31679945'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a536371b-ebc4-43aa-a5f2-a1ca432ebbc1">Hematopoietic cell transplant for metastatic germ cell tumors</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic cell transplant for metastatic germ cell tumors (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>EC regimen: </i>
<b>IV:</b> 700 mg/m<sup>2</sup>/day for 3 days beginning 5 days prior to peripheral cell infusion (in combination with etoposide) for 2 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17652649']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17652649'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>TI-CE regimen:</i>
<b> IV:</b> Target AUC 7 to 8 (in combination with etoposide) on days 1 to 3 followed by autologous stem cell support every 21 to 28 days for 3 cycles (cycles 3 to 5). Cycles 1 and 2 consisted of paclitaxel, ifosfamide, and mesna. Refer to protocol for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20194867']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20194867'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4ebbaa33-8ab0-44b8-a662-fd68c7d18267">Hodgkin lymphoma, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma, relapsed or refractory (off-label use):</b>
<b>IV:</b> Target AUC 5 (maximum dose: 800 mg) on day 2 every 2 weeks (in combination with ifosfamide and etoposide) for 2 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11157476']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11157476'])">Ref</a></span>) <b>or</b> Target AUC 5 on day 1 (in combination with gemcitabine and dexamethasone) every 3 weeks for up to 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20578815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20578815'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4b00a027-bd66-4d8a-903c-6d47086c0533">Malignant pleural mesothelioma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malignant pleural mesothelioma (off-label use):</b>
<b>IV:</b> Target AUC 5 on day 1 every 3 weeks (in combination with pemetrexed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16549838']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16549838'])">Ref</a></span>) <b>or </b>Target AUC 5 on day 1 every 3 weeks (in combination with pemetrexed) until disease progression, unacceptable toxicity, or for a maximum of 9 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18156144']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18156144'])">Ref</a></span>) <b>or </b>Target AUC 5 on day 1 every 3 weeks (in combination with pemetrexed) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18594322']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18594322'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="415e018e-821a-43c7-997f-06babe54bbcd">Melanoma, advanced or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma, advanced or metastatic (off-label use; if cytotoxic chemotherapy is indicated):</b>
<b>IV:</b> Target AUC 6 on day 1 every 3 weeks (in combination with paclitaxel) for 4 cycles followed by (if dose not previously reduced) Target AUC 5 on day 1 every 3 weeks (in combination with paclitaxel) for up to 6 additional cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23248256']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23248256'])">Ref</a></span>) <b>or</b> Target AUC 2 on days 1, 8, and 15 every 4 weeks (in combination with paclitaxel) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16342250']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16342250'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9d1c0ac3-f816-496c-b795-1ed8749c88b2">Merkel cell carcinoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Merkel cell carcinoma (off-label use): IV:</b> Target AUC 4.5 on day 1 of weeks 1, 4, 7, and 10 (in combination with etoposide and synchronous radiation therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14645427']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14645427'])">Ref</a></span>) <b>or</b> Target AUC 2 on day 1 weekly for up to 5 doses (administered concurrently with radiation), followed (beginning 3 weeks after radiation therapy) by carboplatin with a Target AUC of 4.5 on day 1 (in combination with etoposide) every 3 weeks for 3 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18707820']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18707820'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="91b258ee-c6df-470d-af95-94d7c9cb30d4">Neuroendocrine tumors, advanced, atypical or poorly differentiated, nonpulmonary</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroendocrine tumors, advanced, atypical or poorly differentiated, nonpulmonary (off-label use): IV:</b> Target AUC 6 on day 1 every 3 weeks (in combination with etoposide) for 4 to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20664477','lexi-content-ref-11697833']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20664477','lexi-content-ref-11697833'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="24894929-2b6f-4f03-9c28-dac7cd8e83c1">Non-Hodgkin lymphomas, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-Hodgkin lymphomas, relapsed/refractory (off-label use):</b>
<b>IV:</b> Target AUC 5 (maximum dose: 800 mg) every ~2 weeks for 3 cycles (in combination with rituximab, ifosfamide, and etoposide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14739217']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14739217'])">Ref</a></span>) <b>or</b> Target AUC 5 on day 1 (in combination with gemcitabine and dexamethasone ± rituximab) every 3 weeks for up to 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20578815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20578815'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c818fdd2-0859-4362-9aae-976c7de99cda">Non–small cell lung cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–small cell lung cancer (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nonsquamous cell histology:</i>
<b> IV: </b>Target AUC 6 on day 1 every 3 weeks for 4 to 6 cycles (in combination with atezolizumab, bevacizumab, and paclitaxel) followed by atezolizumab/bevacizumab maintenance therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29863955']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29863955'])">Ref</a></span>) <b>or</b> Target AUC 6 every 3 weeks for 4 to 6 cycles (in combination with atezolizumab and paclitaxel [protein bound]) followed by atezolizumab maintenance therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31122901']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31122901'])">Ref</a></span>)<b> or </b>Target AUC 5 or 6 every 3 weeks (in combination with pemetrexed, nivolumab, and ipilimumab) for 2 cycles; nivolumab/ipilimumab therapy continued until disease progression, unacceptable toxicity, or for up to 2 years in patients without disease progression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33476593']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33476593'])">Ref</a></span>)<b> or</b> Target AUC 6 on day 1 every 3 weeks (in combination with pemetrexed and bevacizumab) for up to 4 cycles followed by maintenance therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24145346']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24145346'])">Ref</a></span>) <b>or</b> Target AUC 5 every 3 weeks (in combination with pemetrexed and pembrolizumab) for 4 cycles followed by pembrolizumab/pemetrexed maintenance therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29658856','lexi-content-ref-27745820']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29658856','lexi-content-ref-27745820'])">Ref</a></span>)<b> or</b> Target AUC 6 on day 1 every 3 weeks (in combination with bevacizumab and paclitaxel) for 6 cycles in the absence of disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17167137']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17167137'])">Ref</a></span>) <b>or</b> Target AUC 5 or 6 on day 1 every 3 weeks (in combination with pemetrexed, and durvalumab and tremelimumab) for 4 cycles, followed by tremelimumab (for 1 additional dose), durvalumab, and optional pemetrexed maintenance therapy if eligible; continue durvalumab and pemetrexed until disease progression or unacceptable toxicity; refer to protocol for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36327426']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36327426'])">Ref</a></span>) <b>or</b> Target AUC 5 or 6 on day 1 every 3 weeks (in combination with cemiplimab and pemetrexed) for 4 cycles, followed by pemetrexed maintenance therapy and cemiplimab until disease progression or unacceptable toxicity, or for up to 108 weeks; refer to protocol for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36008722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36008722'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Squamous cell histology:</i>
<b> IV: </b>Target AUC 6 on day 1 every 3 weeks for 4 cycles (in combination with pembrolizumab and either paclitaxel or paclitaxel [protein bound]) followed by pembrolizumab maintenance therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30280635']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30280635'])">Ref</a></span>) <b>or </b>Target AUC 6 every 3 weeks (in combination with paclitaxel, nivolumab, and ipilimumab) for 2 cycles; nivolumab/ipilimumab therapy continued until disease progression, unacceptable toxicity, or for up to 2 years in patients without disease progression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33476593']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33476593'])">Ref</a></span>) <b>or</b> Target AUC 5 or 6 on day 1 every 3 weeks (in combination with gemcitabine, and durvalumab and tremelimumab) for 4 cycles, followed by tremelimumab (for 1 additional dose) and durvalumab; continue durvalumab until disease progression or unacceptable toxicity; refer to protocol for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36327426']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36327426'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nonsquamous or squamous cell histology:</i>
<b>IV:</b> Target AUC 5 or 6 on day 1 every 3 weeks (in combination with paclitaxel [protein bound], and durvalumab and tremelimumab) for 4 cycles, followed by tremelimumab (for 1 additional dose) and durvalumab; continue durvalumab until disease progression or unacceptable toxicity; refer to protocol for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36327426']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36327426'])">Ref</a></span>) <b>or</b> Target AUC 5 or 6 on day 1 every 3 weeks (in combination with cemiplimab and paclitaxel) for 4 cycles, followed by cemiplimab until disease progression or unacceptable toxicity, or for up to 108 weeks; refer to protocol for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36008722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36008722'])">Ref</a></span>) <b>or</b> Target AUC 5 or 6 on day 1 every 3 weeks (in combination with paclitaxel and nivolumab; neoadjuvant therapy) for up to 3 cycles; refer to protocol for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35403841']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35403841'])">Ref</a></span>) <b>or</b> Target AUC 6 on day 1 every 4 weeks (in combination with paclitaxel) for up to 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18512224']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18512224'])">Ref</a></span>) <b>or</b> Target AUC 6 on day 1 every 3 weeks (in combination with paclitaxel) for 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18809614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18809614'])">Ref</a></span>)<b> or</b> Target AUC 5 on day 1 every 3 weeks (in combination with pemetrexed <b>or </b>gemcitabine) for up to 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19433683']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19433683'])">Ref</a></span>)<b> or </b>Target AUC 6 on day 1 every 3 weeks (in combination with paclitaxel [protein bound]) for at least 6 cycles or until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22547591']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22547591'])">Ref</a></span>) <b>or </b>Target AUC 6 on day 1 every 3 weeks (in combination with docetaxel) for at least 6 cycles or until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12837811']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12837811'])">Ref</a></span>) <b>or </b>Target AUC 2 every week for 7 weeks, then Target AUC 6 every 3 weeks for 2 consolidation cycles (in combination with paclitaxel and radiation therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16087941']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16087941'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8ca88c47-fed2-4025-88d5-3331e749f45f">Ovarian cancer, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovarian cancer, advanced:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Advanced ovarian cancer (off-label dosing): </i>
<b>IV: </b>Target AUC 5 or 6 on day 1 every 3 weeks (in combination with paclitaxel) for 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31791688']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31791688'])">Ref</a></span>) <b>or</b> Target AUC 2 once weekly (in combination with weekly paclitaxel) for 18 consecutive weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31791688','lexi-content-ref-24582486']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31791688','lexi-content-ref-24582486'])">Ref</a></span>) <b>or </b>Target AUC 5 every 3 weeks (in combination with docetaxel) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15547181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15547181'])">Ref</a></span>) <b>or</b> Target AUC 6 on day 1 every 3 weeks (in combination with bevacizumab [delayed until cycle 2] and paclitaxel) for up to 6 cycles, followed by bevacizumab monotherapy for a total of up to 22 cycles or until disease progression (whichever occurs earlier) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22204724']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22204724'])">Ref</a></span>) <b>or</b> Target AUC 5 on day 1 every 4 weeks (in combination with doxorubicin [liposomal]) for at least 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20498395']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20498395'])">Ref</a></span>) <b>or </b>Target AUC 5 on day 1 every 4 weeks (in combination with doxorubicin [liposomal] and bevacizumab) for up to 6 cycles, followed by bevacizumab maintenance; refer to protocol for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32305099']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32305099'])">Ref</a></span>) <b>or</b> Target AUC 4 on day 1 every 3 weeks (in combination with gemcitabine and bevacizumab) for 6 to 10 cycles, followed by bevacizumab maintenance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22529265']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22529265'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Neoadjuvant therapy (off-label schedule):</i>
<b>Note:</b> According to guidelines from the Society of Gynecologic Oncology (SGO) and American Society of Clinical Oncology (ASCO) for neoadjuvant chemotherapy in newly diagnosed advanced ovarian cancer, neoadjuvant therapy should be utilized only in properly selected patients. Selection criteria include patients with newly diagnosed suspected stage IIIC or IV ovarian cancer who have a high perioperative risk profile and/or a low likelihood of achieving cytoreduction to &lt;1 cm of residual disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27502591']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27502591'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> Target AUC 5 or 6 on day 1 every 3 weeks (either as a single agent or in combination with paclitaxel) for 3 neoadjuvant cycles, followed by debulking surgery, followed by 3 additional chemotherapy cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26002111']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26002111'])">Ref</a></span>) <b>or</b> Target AUC 5 on day 1 every 3 weeks (in combination with paclitaxel) for 3 neoadjuvant cycles, followed by debulking surgery, followed by 3 additional chemotherapy cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20818904']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20818904'])">Ref</a></span>) <b>or</b> Target AUC 5 on day 1 every 3 weeks (in combination with paclitaxel) for 3 to 4 neoadjuvant cycles, followed by debulking surgery, followed by 2 to 3 additional chemotherapy cycles, for a total of 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26998845']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26998845'])">Ref</a></span>) <b>or </b>Target AUC 5 or 6 on day 1 every 3 weeks (in combination with paclitaxel) for a total of 6 cycles, with debulking surgery occurring after cycles 3 to 6 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31791688']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31791688'])">Ref</a></span>) <b>or </b>Target AUC 2 on days 1, 8, and 15 every 3 weeks (in combination with paclitaxel) for a total of 6 cycles, with debulking surgery occurring after cycles 3 to 6 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31791688']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31791688'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Malignant germ cell tumor (off-label dosing): </i>
<b>IV:</b> 400 mg/m<sup>2</sup> on day 1 (in combination with etoposide) every 4 weeks for 3 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15581952']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15581952'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Manufacturer's labeling: </i>
<b>IV:</b> Dosing in the prescribing information may not reflect current clinical practice. 360 mg/m<sup>2</sup> every 4 weeks (as a single agent) <b>or</b> 300 mg/m<sup>2</sup> every 4 weeks (in combination with cyclophosphamide) for 6 cycles <b>or</b> Target AUC 4 to 6 (single agent; in previously treated patients).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="34a0d01f-7598-4295-91fc-098cdd1ce6dd">Prostate cancer, metastatic, castration resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, metastatic, castration resistant (off-label use): IV: </b>Target AUC 4 on day 1 every 3 weeks (in combination with cabazitaxel, growth factor support, and prednisone) until disease progression or unacceptable toxicity for up to 10 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31515154']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31515154'])">Ref</a></span>) <b>or</b> Target AUC 5 on day 1 every 3 weeks (in combination with docetaxel) for at least 4 cycles or until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23649003']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23649003'])">Ref</a></span>) <b>or</b> Target AUC 5 on day 1 every 3 weeks (in combination with etoposide) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19179557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19179557'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bbb6f1a7-0651-4365-8e89-a7d3245972cd">Sarcomas</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sarcomas (Ewing sarcoma, osteosarcoma) (off-label uses):</b> Adults ≤22 years of age: <b>IV:</b> 400 mg/m<sup>2</sup>/day for 2 days every 21 days (in combination with ifosfamide and etoposide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15503297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15503297'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="458043c8-a34c-4eaf-b646-6c3a69473044">Small cell lung cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Small cell lung cancer (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extensive stage disease:</i>
<b>IV: </b>Target AUC 5 on day 1 every 3 weeks (in combination with etoposide) for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19720897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19720897'])">Ref</a></span>) <b>or </b>Target AUC 5 on day 1 every 3 weeks (in combination with irinotecan) for up to 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18779613']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18779613'])">Ref</a></span>) <b>or</b> Target AUC 5 on day 1 every 28 days (in combination with irinotecan) for 2 to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16423848']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16423848'])">Ref</a></span>)<b> or</b> Target AUC 5 on day 1 every 3 weeks (in combination with etoposide and atezolizumab) for 4 induction cycles, followed by atezolizumab maintenance therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30280641']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30280641'])">Ref</a></span>) <b>or </b>Target AUC 5 or 6 on day 1 every 3 weeks (in combination with etoposide and durvalumab) for 4 cycles, followed by durvalumab maintenance therapy until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31590988']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31590988'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Limited stage disease: </i>
<b>IV: </b>Target AUC 6 on day 1 every 3 weeks (in combination with etoposide) for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11697833']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11697833'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Relapsed disease (diagnosed initially as limited or extensive stage):</i>
<b>IV: </b>Target AUC 5 on day 1 every 3 weeks (in combination with etoposide) for a maximum of 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32888454']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32888454'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="88312d94-dbe6-4c52-8817-5c854f34ab5a">Testicular cancer, early stage, adjuvant treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Testicular cancer, early stage, adjuvant treatment (off-label use):</b>
<b>IV:</b> Target AUC 7 as a single, one-time dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21282539']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21282539'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a05ebca3-baca-4a64-aba6-4b3cf5c4fadf">Thymoma or thymic malignancies, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thymoma or thymic malignancies, advanced (off-label use):</b>
<b>IV:</b> Target AUC 6 on day 1 every 3 weeks (in combination with paclitaxel) for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25403584','lexi-content-ref-21502559']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25403584','lexi-content-ref-21502559'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dcf9a493-2b6b-462b-ae42-474e90075db4">Thyroid carcinoma, anaplastic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyroid carcinoma, anaplastic (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Adjuvant or radiosensitizing therapy:</i>
<b> IV: </b>Target AUC 2 once weekly (in combination with weekly paclitaxel) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23130564']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23130564'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Advanced or metastatic disease: </i>
<b>IV:</b> Target AUC 5 to 6 on day 1 every 3 weeks (in combination with paclitaxel) for 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23130564','lexi-content-ref-23721245']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23130564','lexi-content-ref-23721245'])">Ref</a></span>) <b>or</b> Target AUC 2 once weekly (in combination with weekly paclitaxel) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23130564']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23130564'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="43643979-57e2-4862-91c6-87fa4ec92fb9">Unknown primary cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Unknown primary cancer (off-label use): IV:</b> Target AUC 6 on day 1 every 3 weeks (in combination with paclitaxel) for up to 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10963638']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10963638'])">Ref</a></span>) <b>or</b> Target AUC 6 on day 1 every 3 weeks (in combination with docetaxel) for up to 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10761758']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10761758'])">Ref</a></span>) <b>or</b> Target AUC 6 on day 1 every 3 weeks (in combination with paclitaxel and etoposide) for 2 to 4 cycles, followed by paclitaxel monotherapy (in patients with objective response or stable disease) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16877720']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16877720'])">Ref</a></span>), or for a minimum of 4 and a maximum of 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20164695']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20164695'])">Ref</a></span>) <b>or</b> Target AUC 5 on day 1 every 4 weeks (in combination with irinotecan) for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19088717']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19088717'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50992094"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Kenar D. Jhaveri, MD; Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> The Calvert formula, where <b>Total dose (mg) = Target AUC × (GFR + 25)</b>, is prospectively validated to yield AUC that correlates with kidney function and acceptable hematologic toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2681557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2681557'])">Ref</a></span>)<b>.</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Formula-based dosing:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> Target the usual indication-specific AUC using the Calvert formula (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26351333','lexi-content-ref-2681557','lexi-content-ref-30942181','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26351333','lexi-content-ref-2681557','lexi-content-ref-30942181','lexi-content-ref-Manu.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Some studies suggest that the CKD-EPI equation (with the BSA adjusted so that kidney function is estimated in mL/minute) estimates kidney function for the Calvert equation more accurately than Cockcroft-Gault (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28686534','lexi-content-ref-33297846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28686534','lexi-content-ref-33297846'])">Ref</a></span>). Measured GFR is preferred, especially when the intent is curative or if the patient is at extremes of body composition (size or muscle mass) or has an eGFR ≤45 mL/minute/1.73 m<sup>2</sup> or &gt;125 mL/minute/1.73 m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26351333']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26351333'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Manufacturer's labeling (single-agent therapy):</b></p>
<p style="text-indent:-2em;margin-left:6em;">When the usual recommended dose is: <b>IV: </b>360 mg/m<sup>2</sup> every 4 weeks:</p>
<p style="text-indent:-2em;margin-left:8em;">Baseline CrCl ≥60 mL/minute: <b>IV: </b>No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:8em;">Baseline CrCl 41 to 59 mL/minute: <b>IV: </b>Initiate at 250 mg/m<sup>2</sup> and adjust subsequent doses based on bone marrow toxicity.</p>
<p style="text-indent:-2em;margin-left:8em;">Baseline CrCl 16 to 40 mL/minute: <b>IV: </b>Initiate at 200 mg/m<sup>2</sup> and adjust subsequent doses based on bone marrow toxicity.</p>
<p style="text-indent:-2em;margin-left:8em;">Baseline CrCl ≤15 mL/minute: <b>IV: </b>There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥125 mL/minute/1.73 m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Young patients (&lt;55 years of age) admitted post-trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. Measured CrCl or GFR is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26351333','lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26351333','lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>Target the usual indication-specific AUC using the Calvert formula (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). In patients with augmented kidney function, as confirmed by a measured GFR or CrCl, capping CrCl or total dose per AUC is not recommended as it could lead to underdosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26351333','lexi-content-ref-30336729','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26351333','lexi-content-ref-30336729','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable; extraction ratio of 61% to 82% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24037992']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24037992'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Case reports describe successful use of carboplatin (AUC within 20% of target AUC value) using the Calvert formula and a GFR of 0 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30519478','lexi-content-ref-20563583','lexi-content-ref-11812097']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30519478','lexi-content-ref-20563583','lexi-content-ref-11812097'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>Target the usual indication-specific AUC using the Calvert formula with a GFR of 0 mL/minute; hemodialysis should occur between 12 to 24 hours after carboplatin dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Dialyzable; 14% to 20% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18204842']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18204842'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>Target the usual indication-specific AUC using the Calvert formula with a measured GFR for those with residual kidney function or a GFR of 0 mL/minute for patients without significant residual kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations. The molecular weight of carboplatin is conducive to filtration by CRRT systems. Carboplatin distribution is not influenced by plasma proteins for approximately 6 hours following administration, after which free platinum (active constituent) progressively and irreversibly binds plasma proteins which undergo nonrenal elimination (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1760899']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1760899'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>Target the usual indication-specific AUC using the Calvert formula with empiric GFR values based on institutional specific effluent flow rates for CRRT system. For example, if effluent flow rate is 2,000 mL/hr (33 mL/minute) then use Total dose (mg) = Target AUC × (33 + 25) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989309"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, carboplatin undergoes minimal hepatic metabolism therefore dosage adjustment may not be needed.</p></div>
<div class="block adr drugH1Div" id="F146159"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum calcium (22% to 31%), decreased serum magnesium (29% to 43%), decreased serum potassium (20% to 28%), decreased serum sodium (29% to 47%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastrointestinal pain (17%), nausea (10% to 15%), nausea and vomiting (92%), vomiting (65% to 81%; severe vomiting: 22%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (21% to 90%), leukopenia (15% to 85%), neutropenia (16% to 67%), thrombocytopenia (25% to 62%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase (24% to 37%), increased serum aspartate aminotransferase (15% to 19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (11%), pain (23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Decreased creatinine clearance (27%), increased blood urea nitrogen (14% to 22%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (6%), diarrhea (6%), dysgeusia (1%), stomatitis (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemorrhage (5%; including iatrogenic bleeding)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum bilirubin (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Neurotoxicity (5%), peripheral neuropathy (4% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Visual disturbance (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Ototoxicity (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (6% to 10%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Febrile neutropenia, hemolytic-uremic syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Horita 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction (erythema at injection site, pain at the infection site, swelling at injection site)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Malaise</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Papilledema (hemorrhagic) (Santos-Bueso 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute interstitial nephritis (Asai 2020)</p></div>
<div class="block coi drugH1Div" id="F146174"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">History of severe allergic reaction to carboplatin, cisplatin, other platinum-containing formulations, or any component of the formulation; should not be used in patients with severe bone marrow depression or significant bleeding.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling</i>: Additional contraindications (not in the US labeling): Preexisting severe renal impairment.</p></div>
<div class="block war drugH1Div" id="F146156"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Bone marrow suppression, which may be severe, is dose related; may result in infection (due to neutropenia) or bleeding (due to thrombocytopenia). Anemia (which is cumulative) may require blood transfusion. The median nadir typically occurs at day 21 for single-agent carboplatin. Patients who have received prior myelosuppressive therapy and patients with renal dysfunction are at increased risk for bone marrow suppression.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI toxicity: Nausea and vomiting may occur; antiemetics may be recommended to prevent nausea and vomiting. Nausea and vomiting may be more severe in patients who have received prior emetogenic chemotherapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic function abnormalities: High doses (&gt;4 times the recommended dose) have resulted in severe abnormalities of LFTs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity/anaphylactoid reactions: Anaphylactic-like reactions have been reported with carboplatin; may occur within minutes of administration. Epinephrine, corticosteroids, and antihistamines have been used to treat symptoms. The risk of allergic reactions (including anaphylaxis) is increased in patients previously exposed to platinum therapy. Skin testing and desensitization protocols have been reported (Confina-Cohen 2005; Lee 2004; Markman 2003).</p>
<p style="text-indent:-2em;margin-left:4em;">• Neurotoxicity: Although peripheral neuropathy occurs infrequently, the incidence of peripheral neuropathy is increased in patients &gt;65 years of age and those who have previously received cisplatin treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ototoxicity: Ototoxicity may occur when administered concomitantly with aminoglycosides. Clinically significant hearing loss has been reported to occur in pediatric patients when therapy was administered at higher-than-recommended doses in combination with other ototoxic agents (eg, aminoglycosides). In a study of children receiving carboplatin for the treatment of retinoblastoma, those &lt;6 months of age at treatment initiation were more likely to experience ototoxicity; long-term audiology monitoring is recommended (Qaddoumi 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal toxicity: Carboplatin has a limited potential for nephrotoxicity unless administered concomitantly with aminoglycosides. Use caution with concomitant administration with aminoglycosides or other nephrotoxic medications.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vision loss: Loss of vision (usually reversible within weeks of discontinuing) has been reported with higher-than-recommended doses.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Patients with renal dysfunction are at increased risk for bone marrow suppression.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Taxane derivatives: When administered as sequential infusions, taxane derivatives (docetaxel, paclitaxel) should be administered before the platinum derivatives (carboplatin, cisplatin) to limit myelosuppression and to enhance efficacy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Patients &gt;65 years of age are more likely to develop thrombocytopenia (severe) and peripheral neuropathy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Dosing with Calvert formula: When calculating the carboplatin dose using the Calvert formula and an eGFR, the laboratory method used to measure serum creatinine may impact dosing. Compared to other methods, standardized isotope dilution mass spectrometry (IDMS) may underestimate serum creatinine values in patients with low creatinine values (eg, ≤0.7 mg/dL) and may overestimate GFR in patients with normal renal function. This may result in higher calculated carboplatin doses and increased toxicities. If using IDMS, the FDA recommends that clinicians consider capping estimated GFR at a maximum of 125 mL/minute to avoid potential toxicity.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878368"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Ototoxicity has been reported with platinum-based (ie, cisplatin and carboplatin) chemotherapy; the reported incidence in pediatric patients with cisplatin is 13% to 95% and is highly variable due to different assessment tools, which also affects reported severity levels and risk factor determination. In a multicenter trial of 333 patients (mean age: 4 years; range: 0.3 to 29 years; 80% of patients were &lt;5 years at time of diagnosis) treated for high-risk neuroblastoma with cisplatin induction therapy followed by an HSCT myeloablative regimen which included carboplatin in some patients (ie, multiple-exposure), audiological evaluations (including baseline) were completed using multiple assessment tools. At the time of evaluation, the majority of patients were &lt;5 years of age at time of initial exposure and results showed some degree of hearing loss in ≥64% of patients following single exposure (cisplatin induction) and &gt;80% of those with multiple-exposure (cisplatin induction plus carboplatin myeloablation) regardless of grading scale. Overall, the hearing loss was graded as moderate or severe in 41% to 85% of patients depending on the scale with a higher incidence (66% to 85%) in those with who received both cisplatin induction and carboplatin myeloablation; &gt;50% required a hearing aid (Landier 2014).</p></div>
<div class="block foc drugH1Div" id="F146167"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/5 mL (5 mL); 150 mg/15 mL (15 mL); 450 mg/45 mL (45 mL); 600 mg/60 mL (60 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Paraplatin: 50 mg/5 mL (5 mL [DSC]); 150 mg/15 mL (15 mL [DSC]); 450 mg/45 mL (45 mL [DSC]); 600 mg/60 mL (60 mL [DSC]); 1000 mg/100 mL (100 mL) [pyrogen free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/5 mL (5 mL); 150 mg/15 mL (15 mL); 450 mg/45 mL (45 mL); 600 mg/60 mL (60 mL)</p></div>
<div class="block geq drugH1Div" id="F146152"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323041"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (CARBOplatin Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/5 mL (per mL): $1.98 - $3.22</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg/15 mL (per mL): $1.68 - $2.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">450 mg/45 mL (per mL): $1.14 - $5.39</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">600 mg/60 mL (per mL): $1.00 - $5.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Paraplatin Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg/100 mL (per mL): $1.41</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866199"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/mL (5 mL, 15 mL, 45 mL, 60 mL)</p></div>
<div class="block admp drugH1Div" id="F52612367"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Carboplatin is associated with a high emetic potential in pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30729654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30729654'])">Ref</a></span>); antiemetics are recommended to prevent nausea and vomiting.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: <b>Note:</b> Needles or IV administration sets that contain aluminum should not be used in the preparation or administration of carboplatin; aluminum can react with carboplatin resulting in precipitate formation and loss of potency.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Administer over 15 to 60 minutes although some protocols may require infusions up to 24 hours. When administered as a part of a combination chemotherapy regimen, sequence of administration may vary by regimen; refer to specific protocol for sequence recommendation.</p></div>
<div class="block adm drugH1Div" id="F146171"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Antiemetics may be recommended to prevent nausea and vomiting; depending on the dose, carboplatin is associated with a moderate or high emetic potential in adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse over at least 15 minutes; usually infused over 15 to 60 minutes, although some protocols may require infusions up to 24 hours. When administered as a part of a combination chemotherapy regimen, sequence of administration may vary by regimen; refer to specific protocol for sequence recommendation.</p>
<p style="text-indent:-2em;margin-left:2em;">Needles or IV administration sets that contain aluminum should not be used in the preparation or administration of carboplatin; aluminum can react with carboplatin resulting in precipitate formation and loss of potency.</p></div>
<div class="block hazard drugH1Div" id="F49130923"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block sts drugH1Div" id="F146182"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials at room temperature at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light. Further dilution to a concentration as low as 0.5 mg/mL is stable at room temperature (25°C) for 8 hours in NS or D5W. Stability has also been demonstrated for dilutions in D5W in PVC bags at room temperature for 9 days (Benaji 1994) and for dilutions (0.5 mg/mL, 2 mg/mL, and 4 mg/mL) in NS in PVC bags at room temperature for 24 hours, 24 hours, and 2 days, respectively (Myers 2016); however, the manufacturer recommends use within 8 hours due to lack of preservative. Multidose vials are stable for up to 14 or 15 days after opening when stored at 25°C (77°F) following multiple needle entries (refer to specific product labeling for stability information). Follow USP 797 recommendations for beyond use dates based on the level of risk for preparation.</p></div>
<div class="block usep drugH1Div" id="F53565868"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of advanced ovarian carcinoma (FDA approved in adults); has also been used in the treatment of central nervous system tumors (gliomas, neuroblastomas), retinoblastoma, sarcomas (Ewing sarcoma, osteosarcoma), Wilms tumor, and as a conditioning regimen prior to hematopoietic stem cell transplantation</p></div>
<div class="block mst drugH1Div" id="F146248"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">CARBOplatin may be confused with CISplatin, oxaliplatin</p>
<p style="text-indent:-2em;margin-left:4em;">Paraplatin may be confused with Platinol</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298973"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F146161"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: CARBOplatin may enhance the nephrotoxic effect of Aminoglycosides. Aminoglycosides may enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bexarotene (Systemic): CARBOplatin may increase the serum concentration of Bexarotene (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capecitabine: CARBOplatin may enhance the nephrotoxic effect of Capecitabine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: Platinum Derivatives may decrease the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">SORAfenib: May enhance the adverse/toxic effect of CARBOplatin. CARBOplatin may increase the serum concentration of SORAfenib. Management: Concurrent sorafenib with carboplatin and paclitaxel in patients with squamous cell lung cancer is contraindicated.  Use in other settings is not specifically contraindicated but should be approached with added caution.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taxane Derivatives: Platinum Derivatives may enhance the myelosuppressive effect of Taxane Derivatives. Administer Taxane derivative before Platinum derivative when given as sequential infusions to limit toxicity.  Management: Administer paclitaxel before cisplatin, when given as sequential infusions, to limit toxicity. Problems associated with other taxane/platinum combinations are possible, although unsubstantiated. Administering the taxane before platinum is likely warranted<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topotecan: Platinum Derivatives may enhance the adverse/toxic effect of Topotecan.  Management: Consider administering platinum derivatives after topotecan when possible to minimize toxicity or using lower doses if administering platinum derivatives prior to topotecan. Monitor for hematologic toxicity (eg, neutropenia, thrombocytopenia).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53539386"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">In general, patients who could become pregnant should use effective contraception during systemic anticancer therapy and for 3 to 6 months after the last dose. Patients with partners who could become pregnant should use effective contraception during treatment and for 3 to 6 months after the last dose of systemic anticancer therapy (ESMO [Peccatori 2013]).</p>
<p style="text-indent:0em;margin-top:2em;">Carboplatin may increase the risk of ovarian dysfunction (ACOG 2018). Carboplatin may have an intermediate risk of treatment-related azoospermia and male infertility (ESMO [Lambertini 2020]). Recommendations are available for fertility preservation of male and female patients to be treated with anticancer agents (ASCO [Oktay 2018]; Klipstein 2020).</p></div>
<div class="block pri drugH1Div" id="F10923584"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Carboplatin crosses the human placenta (Benoit 2021).</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following maternal use of carboplatin during pregnancy are available (Bernardini 2022; NTP 2013; Pei 2022). Carboplatin may cause fetal harm if administered during pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy. The guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team) approach. In general, if chemotherapy is indicated, it should be avoided in the first trimester and there should be a 3-week time period between the last chemotherapy dose and anticipated delivery (for adequate maternal and fetal bone marrow recovery), and chemotherapy should not be administered beyond week 33 of gestation. When indicated, chemotherapy may be administered during the second or third trimester at the same dose and schedule as recommended for nonpregnant patients (Amant 2019; ESMO [Peccatori 2013]).</p>
<p style="text-indent:0em;margin-top:2em;">A long-term observational research study is collecting information about the diagnosis and treatment of cancer during pregnancy. For additional information about the pregnancy and cancer registry or to become a participant, contact Cooper Health (877-635-4499).</p></div>
<div class="block mopp drugH1Div" id="F53565853"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC with differential and platelet count, serum electrolytes, serum creatinine and BUN, nuclear medicine measured GFR or creatinine clearance, liver function tests; audiology evaluations in pediatric patients</p></div>
<div class="block pha drugH1Div" id="F146155"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Carboplatin is a platinum compound alkylating agent which covalently binds to DNA; interferes with the function of DNA by producing interstrand DNA cross-links. Carboplatin is apparently not cell-cycle specific.</p></div>
<div class="block phk drugH1Div" id="F146173"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: 16 L (based on a dose of 300 to 500 mg/m<sup>2</sup>); into liver, kidney, skin, and tumor tissue</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: Carboplatin: 0%; Platinum (from carboplatin): Irreversibly binds to plasma proteins</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Minimally hepatic to aquated and hydroxylated compounds </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: CrCl &gt;60 mL/minute: Carboplatin: 2.6 to 5.9 hours (based on a dose of 300 to 500 mg/m<sup>2</sup>); Platinum (from carboplatin): ≥5 days</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (~70% as carboplatin within 24 hours; 3% to 5% as platinum within 1 to 4 days)</p></div>
<div class="block phksp drugH1Div" id="F51154238"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: In patients with CrCl &lt;60 mL/minute, the total body and renal clearance decreases as CrCl decreases.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F146176"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Kemocarb</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Carboplatino filaxis | Paraplatin rtu</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Carboplatin accord | Carboplatin actavis | Carboplatin d-w | Carboplatin ebewe | Paraplatin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Baxter Carboplatin | Carbaccord | Carboplatin accord | Carboplatin kabi</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Aricarb</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Carboplatin accord | Carboplatin sandoz | Carboplatine | Carboplatine mayne pharma (ben) | Carboplatine mylan | Carboplatinum | Carbosin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">B platin | Citoplatina | Fauldcarbo | Kemocarb | Tevacarbo | Vancel</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Carbo platinum labatec | Carboplatin accord | Carboplatin actavis | Carboplatin ebewe | Carboplatin Mepha | Carboplatin sandoz | Carboplatin Sandoz eco | Carboplatin teva | Paraplatin</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Carbotinol</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Bo bei</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Blastocarb ru | Carboplatino | Cytocarb</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Carbomedac | Carboplatin accord | Carboplatin kabi | Cycloplatin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Axicarb | Carbo | Carbo Pt Ebewe | Carbomedac | Carboplatin accord | Carboplatin actavis | Carboplatin Bendalis | Carboplatin ebewe | Carboplatin Gry | Carboplatin Hexal | Carboplatin hikma | Carboplatin kabi | Carboplatin O.R.C.A.pharm | Carboplatin Omnicare | Carboplatin onkovis | Carboplatin Profusio | Carboplatin Ratiopharm | Carboplatin sandoz | Carboplatin Sun | Carboplatin vitane | Carbox | Eurocarboplatin | Neocarbo | Ribocarbo</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Kemocarb</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Carboplatino</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Carboplatin accord | Carboplatin actavis | Carboplatin kabi | Paraplatin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Carboplatin ebewe | Carboplatin mylan | Carbotinol | Cytocarb | Kemocarb</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Carboplatino Accord | Carboplatino Ferrer Farma | Carboplatino Hikma | Carboplatino Ratiopharm | Carboplatino sandoz | Carboplatino sun | Carboplatino Teva | Ercar | Paraplatin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Carboplatin accord | Carboplatin bmm pharma | Carboplatin mayne | Carbosin | Paraplatin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Carboplatine | Carboplatine actavis | Carboplatine aguettant | Carboplatine Dakota | Carboplatine g gam | Carboplatine kabi | Carboplatine merck | Carboplatine Qualimed | Carboplatine Sun | Carboplatine teva | Carboplatine Winthrop | Paraplatine</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Carboplatin sandoz | Carboplatin Sun | Paraplatin | Trav carboplatin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Carbatacin | Carboplan | Carboplatin ebewe | Carboplatin/hospira | Carbosin | Emorzim | Megaplatin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Carboplatin ebewe | Carbosin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Carboplatin Pfizer | Carboplatin Pliva</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Bopacatin | Carboplatin accord | Carboplatin ebewe | Carboplatin kabi | Carboplatin teva | Carboplatin venus</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Carboplatin Pfizer | Carbosin | Erbakar | Kemobotin | Kemocarb | Sanbeplatin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Paraplatin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Carboplatin ebewe</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Adcarb | Biocarb | Caboo | Carboteen | Carbotero | Carbozar | Cytocarb | Karplat | Paraplatin | Stricarb | Unicarb | Womastin | Zucarb</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Carboplatino | Carboplatino Accord | Carboplatino Ahcl | Carboplatino aurobindo | Carboplatino ebewe | Carboplatino Hikma | Carboplatino may | Carboplatino pfizer | Carboplatino phu | Carboplatino sun</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Carbomerck | Carbomerck merk hoei | Carboplatin Hexal | Carboplatin Sawai | Carboplatin teva kowa | Paraplatin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Adcarb | Kemocarb | Womastin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Canplatin | Carbosin | Carbotinol | Dong a carplan | Neoplatin | Pfizer carboplatin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Carboplan</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Carboplatine mylan | Karboteen | Kemocarb | Megaplatin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Carboplatin accord | Carboplatin actavis | Carboplatin bmm pharma | Carboplatin kabi</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Carboplatin accord | Carboplatin kabi | Cytocarb | Paraplatin</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Acucarb</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Kemocarb | Nuvaplast | Placart</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Carbopa | Kemocarb | Neoplatin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Carboplatin accord | Carboplatin ebewe | Carboplatine | Carboplatine "Eurocept" | Carboplatine fresenius kabi | Carbosin | Paraplatin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Carboplatin accord | Carboplatin actavis | Carboplatin bmm pharma | Carboplatin hospira | Carboplatin meda | Carboplatin teva | Carbosin | Paraplatin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Dbl carboplatin | Paraplatin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Carboplatino</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Actoplatin | Biovinate | Bonaplatin | Carboplatin hospira | Carbotin | Carbotinol | Carbplin | Cisamin | Crobextin | Kemocarb | Naproplat</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Carbosol | Carbotinol | Carplatu | Kemocarb</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Carbomedac | Carboplatin accord | Carboplatin actavis | Carboplatin cancernova | Carboplatin Sun | Cycloplatin | Paract</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Paraplatin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Carboplatin APS | Carboplatina | Carboplatina accord | Carboplatina hikma | Carboplatina Kabi | Nealorin | Novoplatinum</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Carboplatino cipla | Carboplatino libra | Omilipis | Vancel</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Carboplatin actavis | Carboplatin kabi | Carboplatin teva</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Camocarb | Carboplatin Lens | Carboplatin ronc | Carboplatin teva | Cycloplatin | Irinoplat | Kemocarb | Paract | Paraplatin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Carbo cell | Carbotinol | Kemocarb</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Carboplatin accord | Carboplatin actavis | Carboplatin bmm pharma | Carboplatin ebewe | Carboplatin hospira | Carboplatin lederle | Carboplatin Pfizer | Carboplatin pharma | Carboplatin scand pharm | Carboplatin teva | Paraplatin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Bopacatin | Carboplatin ebewe | Carbosin | Karboplatin medac</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Bopacatin | Carbomedac | Carboplatin accord | Carboplatin kabi | Cycloplatin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Carboplatin abic | Carboplatin ebewe | Carboplatin pharma | Carbosin | Kemocarb | Neoplatin | Paraplatin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Carboplatin ebewe | Carboplatine actavis | Cytokar | Karboteen | Megaplatin | Omilipis</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Carbodex | Carboplan | Carboplatin ebewe | Carboplatin Kocak | Carbosin | Carmen | Carplatu | Paraplatin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Caxatin | Kemocarb | Paraplatin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Carbopa | Kemocarb | Paraplatin | Platicarb | Stricarb</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Womastin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Carboplatino | Gadoplatin</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Bocartin | Carbotenol</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Aspen carboplatin | Paraplatin | Spalcarb</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Biocarb | Kemocarb | Womastin</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Kemocarb</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10519590">
<a name="10519590"></a>Abramson DH, Frank CM, Dunkel IJ. A Phase I/II Study of Subconjunctival Carboplatin for Intraocular Retinoblastoma. <i>Ophthalmology.</i> 1999;106(10):1947-1950.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/10519590/pubmed" id="10519590" target="_blank">10519590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11996479">
<a name="11996479"></a>Abu-Ghosh AM, Krailo MD, Goldman SC, et al. Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms tumor: a Children's Cancer Group report. <i>Ann Oncol</i>. 2002;13(3):460-469.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/11996479/pubmed" id="11996479" target="_blank">11996479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22529265">
<a name="22529265"></a>Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. <i>J Clin Oncol</i>. 2012;30(17):2039-2045. doi:10.1200/JCO.2012.42.0505<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/22529265/pubmed" id="22529265" target="_blank">22529265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20486170">
<a name="20486170"></a>Allen S, Wilson MW, Watkins A, et al. Comparison of two methods for carboplatin dosing in children with retinoblastoma. <i>Pediatr Blood Cancer</i>. 2010;55(1):47-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/20486170/pubmed" id="20486170" target="_blank">20486170</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31435648">
<a name="31435648"></a>Amant F, Berveiller P, Boere IA, et al. Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. <i>Ann Oncol</i>. 2019;30(10):1601-1612. doi:10.1093/annonc/mdz228<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/31435648/pubmed" id="31435648" target="_blank">31435648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30045213">
<a name="30045213"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Committee Opinion No. 747: Gynecologic issues in children and adolescent cancer patients and survivors. <i>Obstet Gynecol</i>. 2018;132(2):e67-e77. doi:10.1097/AOG.0000000000002763<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/30045213/pubmed" id="30045213" target="_blank">30045213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23649003">
<a name="23649003"></a>Aparicio AM, Harzstark AL, Corn PG, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. <i>Clin Cancer Res</i>. 2013;19(13):3621-3630. doi:10.1158/1078-0432.CCR-12-3791<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/23649003/pubmed" id="23649003" target="_blank">23649003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children.</i> 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 97, 169.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31834568">
<a name="31834568"></a>Asai A, Katsuno T, Yamaguchi M, et al. Carboplatin-related acute interstitial nephritis in a patient with pancreatic neuroendocrine tumor. <i>CEN Case Rep</i>. 2020;9(2):114-121. doi:10.1007/s13730-019-00437-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/31834568/pubmed" id="31834568" target="_blank">31834568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32888454">
<a name="32888454"></a>Baize N, Monnet I, Greillier L, et al; Groupe Français de Pneumo-Cancérologie 01–13 investigators. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial. <i>Lancet</i>
<i>Oncol</i>. 2020;21(9):1224-1233. doi:10.1016/S1470-2045(20)30461-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/32888454/pubmed" id="32888454" target="_blank">32888454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16342065">
<a name="16342065"></a>Bamias A, Moulopoulos LA, Koutras A, et al. The Combination of Gemcitabine and Carboplatin as First-Line Treatment in Patients With Advanced Urothelial Carcinoma. A Phase II Study of the Hellenic Cooperative Oncology Group. <i>Cancer.</i> 2006;106(2):297-303.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/16342065 /pubmed" id="16342065 " target="_blank">16342065 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16087941">
<a name="16087941"></a>Belani CP, Choy H, Bonomi P, et al. Combined Chemoradiotherapy Regimens of Paclitaxel and Carboplatin for Locally Advanced Non-Small-Cell Lung Cancer: A Randomized Phase II Locally Advanced Multi-Modality Protocol. <i>J Clin Oncol. </i>2005;23(25):5883-5891.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/16087941/pubmed" id="16087941" target="_blank">16087941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8071399">
<a name="8071399"></a>Benaji B, Dine T, Luyckx M, et al. Stability and compatibility of cisplatin and carboplatin with PVC infusion bags. <i>J Clin Pharm Ther.</i> 1994, 19(2):95-100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/8071399/pubmed" id="8071399" target="_blank">8071399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33799824">
<a name="33799824"></a>Benoit L, Mir O, Vialard F, Berveiller P. Cancer during pregnancy: a review of preclinical and clinical transplacental transfer of anticancer agents. <i>Cancers (Basel)</i>. 2021;13(6):1238. doi:10.3390/cancers13061238<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/33799824/pubmed" id="33799824" target="_blank">33799824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36005188">
<a name="36005188"></a>Bernardini F, Ferrandina G, Ricci C, et al. Neoadjuvant chemotherapy in pregnant patients with cervical cancer: a monocentric retrospective study. <i>Curr Oncol</i>. 2022;29(8):5702-5714. doi:10.3390/curroncol29080450<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/36005188/pubmed" id="36005188" target="_blank">36005188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10963638">
<a name="10963638"></a>Briasoulis E, Kalofonos H, Bafaloukos D, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. <i>J Clin Oncol</i>. 2000;18(17):3101-3107. doi:10.1200/JCO.2000.18.17.3101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/10963638/pubmed" id="10963638" target="_blank">10963638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24462742">
<a name="24462742"></a>Bubalo J, Carpenter PA, Majhail N, et al. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. <i>Biol Blood Marrow Transplant</i>. 2014;20(5):600-616.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/24462742/pubmed" id="24462742" target="_blank">24462742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22204724">
<a name="22204724"></a>Burger RA, Brady MF, Bookman MA, et al; Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. <i>N Engl J Med</i>. 2011;365(26):2473-2483. doi: 10.1056/NEJMoa1104390.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/22204724/pubmed" id="22204724" target="_blank">22204724</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31679945">
<a name="31679945"></a>Burtness B, Harrington KJ, Greil R, et al; KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. <i>Lancet</i>. 2019;394(10212):1915-1928. doi:10.1016/S0140-6736(19)32591-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/31679945/pubmed" id="31679945" target="_blank">31679945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7610395">
<a name="7610395"></a>Cairo MS. The Use of Ifosfamide, Carboplatin, and Etoposide in Children With Solid Tumors. <i>Semin Oncol. </i>1995;22(3)(suppl 7):23-27.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/7610395/pubmed" id="7610395" target="_blank">7610395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2681557">
<a name="2681557"></a>Calvert AH, Newell DR, Grumbell LA, et al. Carboplatin Dosage: Prospective Evaluation of a Simple Formula Based on Renal Function. <i>J Clin Oncol.</i> 1989;7(11):1748-1756. doi:10.1200/JCO.1989.7.11.1748<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/2681557/pubmed" id="2681557" target="_blank">2681557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ingenus.1">
<a name="Ingenus.1"></a>Carboplatin [prescribing information]. Lake Forest, IL: Hospira Inc; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pfizer.1">
<a name="Pfizer.1"></a>Carboplatin Injection BP (carboplatin) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18156144">
<a name="18156144"></a>Castagneto B, Botta M, Aitini E, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). <i>Ann Oncol.</i> 2008;19(2):370-373. doi:10.1093/annonc/mdm501<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/18156144/pubmed" id="18156144" target="_blank">18156144</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16549838">
<a name="16549838"></a>Ceresoli GL, Zucali PA, Favaretto AG, et al. Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma. <i>J Clin Oncol.</i> 2006;24(9):1443-1448.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/16549838/pubmed" id="16549838" target="_blank">16549838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15809453">
<a name="15809453"></a>Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. <i>J Clin Oncol.</i> 2005;23(15):3568-3576.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/15809453/pubmed" id="15809453" target="_blank">15809453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3548341">
<a name="3548341"></a>Cheung Y-W, Cradock JC, Vishnuvajjala BR, et al. Stability of cisplatin, iproplatin, carboplatin, and tetraplatin in commonly used Intravenous solutions. <i>Am J Hosp Pharm.</i> 1987;44:124-130.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/3548341/pubmed" id="3548341" target="_blank">3548341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35245079">
<a name="35245079"></a>Chuang LT, Temin S, Berek JS; Management and Care of Patients with Invasive Cervical Cancer Resource-Stratified Guideline Expert Panel. Management and care of patients with invasive cervical cancer: ASCO resource-stratified guideline rapid recommendation update. <i>JCO Glob Oncol</i>. 2022;8:e2200027. doi:10.1200/GO.22.00027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/35245079/pubmed" id="35245079" target="_blank">35245079</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28717717">
<a name="28717717"></a>Chuang LT, Temin S, Camacho R, et al. Management and care of women with invasive cervical cancer: American Society of Clinical Oncology resource-stratified clinical practice guideline. <i>J Glob Oncol</i>. 2016;2(5):311-340. doi:10.1200/JGO.2016.003954<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/28717717/pubmed" id="28717717" target="_blank">28717717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31791688">
<a name="31791688"></a>Clamp AR, James EC, McNeish IA, et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. <i>Lancet</i>. 2019;394(10214):2084-2095. doi:10.1016/S0140-6736(19)32259-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/31791688/pubmed" id="31791688" target="_blank">31791688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11745288">
<a name="11745288"></a>Clark JI, Hofmeister C, Choudhury A, et al. Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma. <i>Cancer.</i> 2001;92(9):2334-2340.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/11745288/pubmed" id="11745288" target="_blank">11745288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26092413">
<a name="26092413"></a>Cohen BH, Geyer JR, Miller DC, et al. Pilot study of intensive chemotherapy with peripheral hematopoietic cell support for children less than 3 years of age with malignant brain tumors, the CCG-99703 phase I/II study. A report from the Children's Oncology Group. <i>Pediatr Neurol</i>. 2015;53(1):31-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/26092413/pubmed" id="26092413" target="_blank">26092413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34534429">
<a name="34534429"></a>Colombo N, Dubot C, Lorusso D, et al; KEYNOTE-826 Investigators. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. <i>N Engl J Med</i>. Published online September 18, 2021. doi:10.1056/NEJMoa2112435<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/34534429/pubmed" id="34534429" target="_blank">34534429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15977213">
<a name="15977213"></a>Confino-Cohen R, Fishman A, Altaras M, et al. Successful carboplatin desensitization in patients with proven carboplatin allergy. <i>Cancer.</i> 2005;104(3):640-643.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/15977213/pubmed" id="15977213" target="_blank">15977213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31515154">
<a name="31515154"></a>Corn PG, Heath EI, Zurita A, et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. <i>Lancet Oncol.</i> 2019;20(10):1432-1443. doi:10.1016/S1470-2045(19)30408-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/31515154/pubmed" id="31515154" target="_blank">31515154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33278935">
<a name="33278935"></a>Cortes J, Cescon DW, Rugo HS, et al; KEYNOTE-355 Investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. <i>Lancet</i>. 2020;396(10265):1817-1828. doi:10.1016/S0140-6736(20)32531-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/33278935/pubmed" id="33278935" target="_blank">33278935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35486426">
<a name="35486426"></a>Damoiseaux D, Calpe S, Rosing H, et al. Presence of five chemotherapeutic drugs in breast milk as a guide for the safe use of chemotherapy during breastfeeding: results from a case series. <i>Clin Pharmacol Ther</i>. 2022;112(2):404-410. doi:10.1002/cpt.2626<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/35486426/pubmed" id="35486426" target="_blank">35486426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18996004">
<a name="18996004"></a>Daw NC, Gregornik D, Rodman J, et al. Renal function after ifosfamide, carboplatin and etoposide (ICE) chemotherapy, nephrectomy and radiotherapy in children with Wilms tumour. <i>Eur J Cancer</i>. 2009;45(1):99-106.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/18996004/pubmed" id="18996004" target="_blank">18996004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22162575">
<a name="22162575"></a>De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. <i>J Clin Oncol</i>. 2012;30(2):191-199. doi:10.1200/JCO.2011.37.3571<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/22162575/pubmed" id="22162575" target="_blank">22162575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11391850">
<a name="11391850"></a>Donahue A, McCune JS, Faucette S, et al. Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing. <i>Cancer Chemother Pharmacol.</i> 2001;47(5):373-379.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/11391850/pubmed" id="11391850" target="_blank">11391850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17652649">
<a name="17652649"></a>Einhorn LH, Williams SD, Chamness A, et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. <i>N Engl J Med.</i> 2007;357(4):340-348.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/17652649/pubmed" id="17652649" target="_blank">17652649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33384141">
<a name="33384141"></a>Eiriksson L, Dean E, Sebastianelli A, et al. Guideline no. 408: management of gestational trophoblastic diseases. <i>J Obstet Gynaecol Can</i>. 2021;43(1):91-105.e1. doi:10.1016/j.jogc.2020.03.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/33384141/pubmed" id="33384141" target="_blank">33384141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15151955">
<a name="15151955"></a>El-Rayes BF, Shields A, Zalupski M, et al. A phase II study of carboplatin and paclitaxel in esophageal cancer. <i>Ann Oncol.</i> 2004;15(6):960-965.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/15151955/pubmed" id="15151955" target="_blank">15151955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29584549">
<a name="29584549"></a>Fader AN, Roque DM, Siegel E, et al. Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu. <i>J Clin Oncol</i>. 2018;36(20):2044-2051. doi: 10.1200/JCO.2017.76.5966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/29584549/pubmed" id="29584549" target="_blank">29584549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26998845">
<a name="26998845"></a>Fagotti A, Ferrandina G, Vizzielli G, et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome. <i>Eur J Cancer</i>. 2016;59:22-33. doi: 10.1016/j.ejca.2016.01.017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/26998845/pubmed" id="26998845" target="_blank">26998845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20194867">
<a name="20194867"></a>Feldman DR, Sheinfeld J, Bajorin DF, et al. TI-CE High Dose Chemotherapy for Patients With Previously Treated Germ Cell Tumors: Results and Prognostic Factor Analysis. <i>J Clin Oncol. </i>2010;28(10):1706-1713.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/20194867/pubmed" id="20194867" target="_blank">20194867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23248256">
<a name="23248256"></a>Flaherty KT, Lee SJ, Zhao F, et al. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. <i>J Clin Oncol</i>. 2013;31(3):373-379. doi:10.1200/JCO.2012.42.1529<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/23248256/pubmed" id="23248256" target="_blank">23248256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24037992">
<a name="24037992"></a>Fong MK, Fetterly GJ Jr, McDougald LJ, Iyer RV. Carboplatin pharmacokinetics in a patient receiving hemodialysis. <i>Pharmacotherapy</i>. 2014;34(2):e9-e13. doi:10.1002/phar.1354<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/24037992/pubmed" id="24037992" target="_blank">24037992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1634913">
<a name="1634913"></a>Forastiere AA, Metch B, Schuller DE, et al. Randomized Comparison of Cisplatin Plus Fluorouracil and Carboplatin Plus Fluorouracil Versus Methotrexate in Advanced Squamous-Cell Carcinoma of the Head and Neck: A Southwest Oncology Group Study. <i>J Clin Oncol. </i>1992;10(8):1245-1251.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/1634913/pubmed" id="1634913" target="_blank">1634913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35403841">
<a name="35403841"></a>Forde PM, Spicer J, Lu S, et al; CheckMate 816 Investigators. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. <i>N Engl J Med</i>. 2022;386(21):1973-1985. doi:10.1056/NEJMoa2202170<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/35403841/pubmed" id="35403841" target="_blank">35403841</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12837811">
<a name="12837811"></a>Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. <i>J Clin Oncol</i>. 2003;21(16):3016-3024. doi:10.1200/JCO.2003.12.046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/12837811/pubmed" id="12837811" target="_blank">12837811</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10623688">
<a name="10623688"></a>Friedman DL, Himelstein B, Shields CL, et al. Chemoreduction and Local Ophthalmic Therapy for Intraocular Retinoblastoma. <i>J Clin Oncol.</i> 2000;18(1):12-17.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/10623688/pubmed" id="10623688" target="_blank">10623688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12576922">
<a name="12576922"></a>Gadgeel SM, Shields AF, Heilbrun LK, et al. Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. <i>Am J Clin Oncol.</i> 2003;26(1):37-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/12576922/pubmed" id="12576922" target="_blank">12576922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29658856">
<a name="29658856"></a>Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer.<i> N Engl J Med</i>. 2018;378(22):2078-2092. doi:10.1056/NEJMoa1801005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/29658856/pubmed" id="29658856" target="_blank">29658856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19998470">
<a name="19998470"></a>Gilheeney SW, Khakoo Y, Souweidane M, et al. Thiotepa/topotecan/carboplatin with autologous stem cell rescue in recurrent/refractory/poor prognosis pediatric malignancies of the central nervous system. <i>Pediatr Blood Cancer</i>. 2010;54(4):591-595.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/19998470/pubmed" id="19998470" target="_blank">19998470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36008722">
<a name="36008722"></a>Gogishvili M, Melkadze T, Makharadze T, et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. <i>Nat Med.</i> 2022;28(11):2374-2380. doi:10.1038/s41591-022-01977-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/36008722/pubmed" id="36008722" target="_blank">36008722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20578815">
<a name="20578815"></a>Gopal AK, Press OW, Shustov AR, et al. Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium. <i>Leuk Lymphoma</i>. 2010;51(8):1523-1529. doi:10.3109/10428194.2010.491137<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/20578815/pubmed" id="20578815" target="_blank">20578815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10761758">
<a name="10761758"></a>Greco FA, Erland JB, Morrissey LH, et al. Carcinoma of Unknown Primary Site: Phase II Trials With Docetaxel Plus Cisplatin or Carboplatin. <i>Ann Oncol. </i>2000;11(2):211-215.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/10761758/pubmed" id="10761758" target="_blank">10761758</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23087196">
<a name="23087196"></a>Griffin SJ, Milla M, Baker TE, Liu T, Wang H, Hale TW. Transfer of carboplatin and paclitaxel into breast milk. <i>J Hum Lact</i>. 2012;28(4):457-459. doi:10.1177/0890334412459374<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/23087196/pubmed" id="23087196" target="_blank">23087196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22473167">
<a name="22473167"></a>Griggs JJ, Mangu PB, Anderson H, et al; American Society of Clinical Oncology. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol.</i> 2012;30(13):1553-1561. doi:10.1200/JCO.2011.39.9436<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/22473167/pubmed" id="22473167" target="_blank">22473167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19433683">
<a name="19433683"></a>Gronberg BH, Bremnes RM, Flotten O, et al. Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin as First-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer. <i>J Clin Oncol.</i> 2009;27(19):3217-3224.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/19433683/pubmed" id="19433683" target="_blank">19433683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GOG.1">
<a name="GOG.1"></a>Gynecologic Oncology Group (GOG). DiSaia PJ, Copeland LJ. <i>Gynecologic Oncology Group newsletter.</i> 2011. Accessed April 29, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23414589">
<a name="23414589"></a>Haddad R, O'Neill A, Rabinowits G, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. <i>Lancet Oncol</i>. 2013;14(3):257-264.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/23414589/pubmed" id="23414589" target="_blank">23414589</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20164695">
<a name="20164695"></a>Hainsworth JD, Spigel DR, Clark BL, et al. Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium trial. <i>Cancer J</i>. 2010;16(1):70-75. doi:10.1097/PPO.0b013e3181c6aa89<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/20164695/pubmed" id="20164695" target="_blank">20164695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16877720">
<a name="16877720"></a>Hainsworth JD, Spigel DR, Litchy S, et al. Phase II Trial of Paclitaxel, Carboplatin, and Etoposide in Advanced Poorly Differentiated Neuroendocrine Carcinoma: A Minnie Pearl Cancer Research Network Study. <i>J Clin Oncol.</i> 2006;24(22):3548-3554.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/16877720/pubmed" id="16877720" target="_blank">16877720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29045554">
<a name="29045554"></a>Han HS, Diéras V, Robson M, et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. <i>Ann Oncol.</i> 2018;29(1):154-161. doi:10.1093/annonc/mdx505<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/29045554/pubmed" id="29045554" target="_blank">29045554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33591844">
<a name="33591844"></a>Hanna NH, Robinson AG, Temin S, et al. Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update. <i>J Clin Oncol</i>. 2021;39(9):1040-1091. doi:10.1200/JCO.20.03570<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/33591844/pubmed" id="33591844" target="_blank">33591844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31990617">
<a name="31990617"></a>Hanna NH, Schneider BJ, Temin S, et al. Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO and OH (CCO) joint guideline update. <i>J Clin Oncol</i>. 2020;38(14):1608-1632. doi:10.1200/JCO.19.03022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/31990617/pubmed" id="31990617" target="_blank">31990617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18779613">
<a name="18779613"></a>Hermes A, Bergman B, Bremnes R, et al. Irinotecan Plus Carboplatin Versus Oral Etoposide Plus Carboplatin in Extensive Small-Cell Lung Cancer: A Randomized Phase III Trial. <i>J Clin Oncol.</i> 2008;26(26):4261-4267.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/18779613/pubmed" id="18779613" target="_blank">18779613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18204842">
<a name="18204842"></a>Heijns JB, van der Burg ME, van Gelder T, et al. Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment. <i>Cancer Chemother Pharmacol</i>. 2008;62(5):841-847. doi:10.1007/s00280-007-0671-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/18204842/pubmed" id="18204842" target="_blank">18204842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32658626">
<a name="32658626"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. <i>J Clin Oncol</i>. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/32658626/pubmed" id="32658626" target="_blank">32658626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25403584">
<a name="25403584"></a>Hirai F, Yamanaka T, Taguchi K, et al; West Japan Oncology Group. A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L. <i>Ann Oncol</i>. 2015;26(2):363-368. doi:10.1093/annonc/mdu541<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/25403584/pubmed" id="25403584" target="_blank">25403584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34505396">
<a name="34505396"></a>Horita N, Miyagi E, Mizushima T, et al. Severe anaphylaxis caused by intravenous anti-cancer drugs. <i>Cancer Med</i>. 2021;10(20):7174-7183. doi:10.1002/cam4.4252<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/34505396/pubmed" id="34505396" target="_blank">34505396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30280641">
<a name="30280641"></a>Horn L, Mansfield AS, Szczęsna A, et al; IMpower133 Study Group. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. <i>N Engl J Med</i>. 2018;379(23):2220-2229. doi: 10.1056/NEJMoa1809064.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/30280641/pubmed" id="30280641" target="_blank">30280641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25847936">
<a name="25847936"></a>Isakoff SJ, Mayer EL, He L, et al. TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. <i>J Clin Oncol</i>. 2015;33(17):1902-1909. doi:10.1200/JCO.2014.57.6660<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/25847936/pubmed" id="25847936" target="_blank">25847936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28686534">
<a name="28686534"></a>Janowitz T, Williams EH, Marshall A, et al. New model for estimating glomerular filtration rate in patients with cancer. <i>J Clin Oncol</i>. 2017;35(24):2798-2805. doi:10.1200/JCO.2017.72.7578<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/28686534/pubmed" id="28686534" target="_blank">28686534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20118214">
<a name="20118214"></a>Janus N, Thariat J, Boulanger H, et al. Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients. <i>Ann Oncol. </i>2010;21(7):1395-1403.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/20118214/pubmed" id="20118214" target="_blank">20118214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32516007">
<a name="32516007"></a>Johnson HM, Mitchell KB; Academy of Breastfeeding Medicine. ABM clinical protocol #34: breast cancer and breastfeeding. <i>Breastfeed Med</i>. 2020;15(7):429-434. doi:10.1089/bfm.2020.29157.hmj<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/32516007/pubmed" id="32516007" target="_blank">32516007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36327426">
<a name="36327426"></a>Johnson ML, Cho BC, Luft A, et al; POSEIDON investigators. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study. <i>J Clin Oncol.</i> Published online November 3, 2022. doi:10.1200/JCO.22.00975<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/36327426/pubmed" id="36327426" target="_blank">36327426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26002111">
<a name="26002111"></a>Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. <i>Lancet</i>. 2015;386(9990):249-257. doi: 10.1016/S0140-6736(14)62223-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/26002111/pubmed" id="26002111" target="_blank">26002111</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14739217">
<a name="14739217"></a>Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as Second-Line Therapy before Autologous Stem Cell Transplantation for Relapsed or Primary Refractory Diffuse Large B-Cell Lymphoma. <i>Blood. </i>2004;103(10):3684-3688.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/14739217/pubmed" id="14739217" target="_blank">14739217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25012155">
<a name="25012155"></a>Kim R, Byer J, Fulp WJ, Mahipal A, Dinwoodie W, Shibata D. Carboplatin and paclitaxel treatment is effective in advanced anal cancer. <i>Oncology</i>. 2014;87(2):125-132. doi:10.1159/000361051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/25012155/pubmed" id="25012155" target="_blank">25012155</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29346042">
<a name="29346042"></a>Kindler HL, Ismaila N, Armato SG 3rd, et al. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2018;36(13):1343-1373. doi:10.1200/JCO.2017.76.6394<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/29346042/pubmed" id="29346042" target="_blank">29346042</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25732161">
<a name="25732161"></a>Kitagawa R, Katsumata N, Shibata T, et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. <i>J Clin Oncol</i>. 2015;33(19):2129-2135. doi:10.1200/JCO.2014.58.4391<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/25732161/pubmed" id="25732161" target="_blank">25732161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32071259">
<a name="32071259"></a>Klipstein S, Fallat ME, Savelli S; Committee on Bioethics; section on hematology/oncology; section on surgery. Fertility preservation for pediatric and adolescent patients with cancer: medical and ethical considerations. <i>Pediatrics</i>. 2020;145(3):e20193994. doi:10.1542/peds.2019-3994<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/32071259/pubmed" id="32071259" target="_blank">32071259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17194908">
<a name="17194908"></a>Kondagunta GV, Bacik J, Sheinfeld J, et al, “Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin Plus Etoposide in Previously Treated Germ Cell Tumors,” <i>J Clin Oncol</i>, 2007, 25(1):85-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/17194908/pubmed" id="17194908" target="_blank">17194908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30519478">
<a name="30519478"></a>Kondo M, Naiki T, Hotta Y, et al. Investigation of tolerability and quality of life for carboplatin-based chemotherapy in an elderly urothelial carcinoma patient undergoing hemodialysis: a case report. <i>J Pharm Health Care Sci</i>. 2018;4:29. doi:10.1186/s40780-018-0124-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/30519478/pubmed" id="30519478" target="_blank">30519478</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol</i>. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23591432">
<a name="23591432"></a>Kunz PL, Reidy-Lagunes D, Anthony LB, et al; North American Neuroendocrine Tumor Society. Consensus guidelines for the management and treatment of neuroendocrine tumors. <i>Pancreas</i>. 2013;42(4):557-577. doi:10.1097/MPA.0b013e31828e34a4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/23591432/pubmed" id="23591432" target="_blank">23591432</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11607767">
<a name="11607767"></a>Kushner BH, Cheung NK, Kramer K, Dunkel IJ, Calleja E, Boulad F. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults. <i>Bone Marrow Transplant</i>. 2001;28(6):551-556.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/11607767/pubmed" id="11607767" target="_blank">11607767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32976936">
<a name="32976936"></a>Lambertini M, Peccatori FA, Demeestere I, et al; ESMO Guidelines Committee. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO clinical practice guidelines. <i>Ann Oncol</i>. 2020;31(12):1664-1678. doi:10.1016/j.annonc.2020.09.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/32976936/pubmed" id="32976936" target="_blank">32976936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24419114">
<a name="24419114"></a>Landier W, Knight K, Wong FL, et al. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group. <i>J Clin Oncol</i>. 2014;32(6):527-534.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/24419114/pubmed" id="24419114" target="_blank">24419114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27745820">
<a name="27745820"></a>Langer CJ, Gadgeel SM, Borghaei H, et al; KEYNOTE-021 investigators. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. <i>Lancet Oncol</i>. 2016;17(11):1497-1508. doi:10.1016/S1470-2045(16)30498-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/27745820/pubmed" id="27745820" target="_blank">27745820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15491759">
<a name="15491759"></a>Lee CW, Matulonis UA, Castells MC. Carboplatin Hypersensitivity: A 6-h 12-Step Protocol Effective in 35 Desensitizations in Patients With Gynecological Malignancies and Mast Cell/IgE-Mediated Reactions. <i>Gynecol Oncol.</i> 2004;95(2):370-376.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/15491759/pubmed" id="15491759" target="_blank">15491759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21502559">
<a name="21502559"></a>Lemma GL, Lee JW, Aisner SC, et al. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. <i>J Clin Oncol</i>. 2011;29(15):2060-2065. doi:10.1200/JCO.2010.32.9607<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/21502559/pubmed" id="21502559" target="_blank">21502559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14528109">
<a name="14528109"></a>Liem RI, Higman MA, Chen AR, Arceci RJ. Misinterpretation of a Calvert-derived formula leading to carboplatin overdose in two children. <i>J Pediatr Hematol Oncol</i>. 2003;25(10):818-821.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/14528109/pubmed" id="14528109" target="_blank">14528109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12228205">
<a name="12228205"></a>Loesch D, Robert N, Asmar L, et al. Phase II multicenter trial of weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. <i>J Clin Oncol</i>. 2002;20(18):3857-3864. doi:10.1200/JCO.2002.08.129<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/12228205/pubmed" id="12228205" target="_blank">12228205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29501363">
<a name="29501363"></a>Loibl S, O’Shaughnessy J, Untch M, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. <i>Lancet Oncol</i>. 2018;19(4):497-509. doi:10.1016/S1470-2045(18)30111-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/29501363/pubmed" id="29501363" target="_blank">29501363</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19179557">
<a name="19179557"></a>Loriot Y, Massard C, Gross-Goupil M, et al. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. <i>Ann Oncol.</i> 2009;20(4):703-708. doi:10.1093/annonc/mdn694<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/19179557/pubmed" id="19179557" target="_blank">19179557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31677820">
<a name="31677820"></a>Lorusso D, Ferrandina G, Colombo N, et al. Carboplatin-paclitaxel compared to carboplatin-paclitaxel-bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 – a randomized phase II trial. <i>Gynecol Oncol</i>. 2019;155(3):406-412. doi:10.1016/j.ygyno.2019.10.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/31677820/pubmed" id="31677820" target="_blank">31677820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1985729">
<a name="1985729"></a>Lovett D, Kelsen D, Eisenberger M, et al. A Phase II Trial of Carboplatin and Vinblastine in the Treatment of Advanced Squamous Cell Carcinoma of the Esophagus. <i>Cancer.</i> 1991;67(2):354-356.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/1985729/pubmed" id="1985729" target="_blank">1985729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15863169">
<a name="15863169"></a>Lurain JR, Nejad B. Secondary chemotherapy for high-risk gestational trophoblastic neoplasia. <i>Gynecol Oncol.</i> 2005;97(2):618-623. doi: 10.1016/j.ygyno.2005.02.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/15863169/pubmed" id="15863169" target="_blank">15863169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22696816">
<a name="22696816"></a>Lurain JR, Schink JC. Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia. <i>J Reprod Med</i>. 2012;57(5-6):219-224.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/22696816/pubmed" id="22696816" target="_blank">22696816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20626175">
<a name="20626175"></a>Lurain JR, Singh DK, Schink JC. Management of metastatic high-risk gestational trophoblastic neoplasia: FIGO stages II-IV: risk factor score &gt; or = 7. <i>J Reprod Med</i>. 2010;55(5-6):199-207.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/20626175/pubmed" id="20626175" target="_blank">20626175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11078494">
<a name="11078494"></a>Mann JR, Raafat F, Robinson K, et al. The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. <i>J Clin Oncol.</i> 2000;18(22):3809-3818.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/11078494/pubmed" id="11078494" target="_blank">11078494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9473756">
<a name="9473756"></a>Mann JR, Raafat F, Robinson K, et al. UKCCSG's germ cell tumour (GCT) studies: improving outcome for children with malignant extracranial non-gonadal tumours--carboplatin, etoposide, and bleomycin are effective and less toxic than previous regimens. United Kingdom Children's Cancer Study Group. <i>Med Pediatr Oncol</i>. 1998;30(4):217-227.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/9473756/pubmed" id="9473756" target="_blank">9473756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8445431">
<a name="8445431"></a>Marina NM, Rodman J, Shema SJ, et al. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. <i>J Clin Oncol</i>. 1993;11(3):554-560.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/8445431/pubmed" id="8445431" target="_blank">8445431</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11283121">
<a name="11283121"></a>Markman M, Kennedy A, Webster K, et al. Combination Chemotherapy With Carboplatin and Docetaxel in the Treatment of Cancers of the Ovary and Fallopian Tube and Primary Carcinoma of the Peritoneum. <i>J Clin Oncol.</i> 2001;19(7):1901-1905.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/11283121/pubmed" id="11283121" target="_blank">11283121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14673050">
<a name="14673050"></a>Markman M, Zanotti K, Peterson G, et al. Expanded Experience With an Intradermal Skin Test to Predict for the Presence or Absence of Carboplatin Hypersensitivity. <i>J Clin Oncol.</i> 2003;21(24):4611-4614.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/14673050/pubmed" id="14673050" target="_blank">14673050</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26324367">
<a name="26324367"></a>Masters GA, Temin S, Azzoli CG, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>J Clin Oncol</i>. 2015;33(30):3488-515. doi:10.1200/JCO.2015.62.1342<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/26324367/pubmed" id="26324367" target="_blank">26324367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33078978">
<a name="33078978"></a>Miller DS, Filiaci VL, Mannel RS, et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209). <i>J Clin Oncol</i>. 2020;38(33):3841-3850. doi:10.1200/JCO.20.01076<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/33078978/pubmed" id="33078978" target="_blank">33078978</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36972026">
<a name="36972026"></a>Mirza MR, Chase DM, Slomovitz BM, et al; RUBY Investigators. Dostarlimab for primary advanced or recurrent endometrial cancer. <i>N Engl J Med</i>. 2023;388(23):2145-2158. doi:10.1056/NEJMoa2216334<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/36972026/pubmed" id="36972026" target="_blank">36972026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Modlin.1">
<a name="Modlin.1"></a>Modlin J and Mancini R. Chemotherapy Administration Sequence: A Review of the Literature and Creation of a Sequencing Chart. <i>J Hematol Oncol.</i> 2011;1(1):17-25. http://issuu.com/theoncologypharmacist/docs/jhop_march2011?mode=embed&amp;layout=http%3A%2F%2Fskin.issuu.com%2Fv%2Fdark%2Flayout.xml&amp;showFlipBtn=true
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21276754">
<a name="21276754"></a>Morgan C, Tillett T, Braybrooke J, et al. Management of Uncommon Chemotherapy-Induced Emergencies. <i>Lancet Oncol.</i> 2011;12(8):806-814.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/21276754/pubmed" id="21276754" target="_blank">21276754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30336729">
<a name="30336729"></a>Morrow A, Garland C, Yang F, De Luna M, Herrington JD. Analysis of carboplatin dosing in patients with a glomerular filtration rate greater than 125 mL/min: to cap or not to cap? A retrospective analysis and review. <i>J Oncol Pharm Pract</i>. 2019;25(7):1651-1657. doi:10.1177/1078155218805136<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/30336729/pubmed" id="30336729" target="_blank">30336729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11157476">
<a name="11157476"></a>Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-Step Comprehensive High-Dose Chemoradiotherapy Second-Line Program for Relapsed and Refractory Hodgkin Disease: Analysis by Intent to Treat and Development of a Prognostic Model. <i>Blood.</i> 2001;97(3):616-623.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/11157476/pubmed" id="11157476" target="_blank">11157476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25122633">
<a name="25122633"></a>Myers AL, Zhang YP, Kawedia JD, et al. Stability study of carboplatin infusion solutions in 0.9% sodium chloride in polyvinyl chloride bags. <i>J Oncol Pharm Pract</i>. 2016;22(1):31-36. doi:10.1177/1078155214546016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/25122633/pubmed" id="25122633" target="_blank">25122633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24736875">
<a name="24736875"></a>National Toxicology Program. NTP monograph: developmental effects and pregnancy outcomes associated with cancer chemotherapy use during pregnancy. <i>NTP Monogr</i>. 2013;(2):i-214.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/24736875/pubmed" id="24736875" target="_blank">24736875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8246021">
<a name="8246021"></a>Newell DR, Pearson AD, Balmanno K, et al. Carboplatin Pharmacokinetics in Children: The Development of a Pediatric Dosing Formula. The United Kingdom Children's Cancer Study Group. <i>J Clin Oncol. </i>1993;11(12):2314-2323.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/8246021/pubmed" id="8246021" target="_blank">8246021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20563583">
<a name="20563583"></a>Oguri T, Shimokata T, Inada M, et al. Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis. <i>Cancer Chemother Pharmacol</i>. 2010;66(4):813-817. doi:10.1007/s00280-010-1366-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/20563583/pubmed" id="20563583" target="_blank">20563583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29620997">
<a name="29620997"></a>Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. <i>J Clin Oncol</i>. 2018;36(19):1994-2001. doi:10.1200/JCO.2018.78.1914<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/29620997/pubmed" id="29620997" target="_blank">29620997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21282539">
<a name="21282539"></a>Oliver RT, Mead GM, Rustin GJ, et al. Randomized Trial of Carboplatin versus Radiotherapy for Stage I Seminoma: Mature Results on Relapse and Contralateral Testis Cancer Rates in MRC TE19/EORTC 30982 Study (ISRCTN27163214). <i>J Clin Oncol.</i> 2011;29(8):957-962.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/21282539/pubmed" id="21282539" target="_blank">21282539</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9126887">
<a name="9126887"></a>Packer RJ, Ater J, Allen J, et al. Carboplatin and Vincristine Chemotherapy for Children With Newly Diagnosed Progressive Low-Grade Gliomas. <i>J Neurosurg.</i> 1997;86(5):747-754.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/9126887/pubmed" id="9126887" target="_blank">9126887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Paraplatin.1">
<a name="Paraplatin.1"></a>Paraplatin (carboplatin) [prescribing information]. Durham, NC: Accord BioPharma Inc; August 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24145346">
<a name="24145346"></a>Patel JD, Socinski MA, Garon EB, et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. <i>J Clin Oncol</i>. 2013;31(34):4349-4357.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/24145346/pubmed" id="24145346" target="_blank">24145346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30729654">
<a name="30729654"></a>Paw Cho Sing E, Robinson PD, Flank J, et al. Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline. <i>Pediatr Blood Cancer</i>. 2019;66(5):e27646. doi: 10.1002/pbc.27646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/30729654/pubmed" id="30729654" target="_blank">30729654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33476593">
<a name="33476593"></a>Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. <i>Lancet Oncol</i>. 2021;22(2):198-211. doi:10.1016/S1470-2045(20)30641-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/33476593/pubmed" id="33476593" target="_blank">33476593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31590988">
<a name="31590988"></a>Paz-Ares L, Dvorkin M, Chen Y, et al; CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. <i>Lancet</i>. 2019;394(10212):1929-1939. doi:10.1016/S0140-6736(19)32222-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/31590988/pubmed" id="31590988" target="_blank">31590988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30280635">
<a name="30280635"></a>Paz-Ares L, Luft A, Vicente D, et al; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. <i>N Engl J Med</i>. 2018;379(21):2040-2051. doi:10.1056/NEJMoa1810865<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/30280635/pubmed" id="30280635" target="_blank">30280635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18308250">
<a name="18308250"></a>Pearson AD, Pinkerton CR, Lewis IJ, et al. High-Dose Rapid and Standard Induction Chemotherapy for Patients Aged Over 1 Year With Stage 4 Neuroblastoma: A Randomised Trial. <i>Lancet Oncol.</i> 2008;9(3):247-256.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/18308250/pubmed" id="18308250" target="_blank">18308250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813932">
<a name="23813932"></a>Peccatori FA, Azim HA Jr, Orecchia R, et al; ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24(suppl 6):vi160-vi170. doi:10.1093/annonc/mdt199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/23813932/pubmed" id="23813932" target="_blank">23813932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19509587">
<a name="19509587"></a>Pectasides D, Fountzilas G, Papaxoinis G, et al. Carboplatin and Paclitaxel in Metastatic or Recurrent Cervical Cancer. <i>Int J Gynecol Cancer. </i>2009;19(4):777-781.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/19509587/pubmed" id="19509587" target="_blank">19509587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18299146">
<a name="18299146"></a>Pectasides D, Xiros N, Papaxoinis G, et al. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. <i>Gynecol Oncol.</i> 2008;109(2):250-254.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/18299146/pubmed" id="18299146" target="_blank">18299146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15150304">
<a name="15150304"></a>Pegram MD, Pienkowski T, Northfelt DW, et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. <i>J Natl Cancer Inst.</i> 2004;96(10):759-769.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/15150304/pubmed" id="15150304" target="_blank">15150304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34865206">
<a name="34865206"></a>Pei Y, Gou Y, Li N, Yang X, Han X, Huiling L. Efficacy and safety of platinum-based chemotherapy for ovarian cancer during pregnancy: a systematic review and meta-analysis. <i>Oncol Ther</i>. 2022;10(1):55-73. doi:10.1007/s40487-021-00179-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/34865206/pubmed" id="34865206" target="_blank">34865206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9779704">
<a name="9779704"></a>Pein F, Michon J, Valteau-Couanet D, et al. High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: a French Society of Pediatric Oncology study.<i> J Clin Oncol</i>. 1998;16(10):3295-3301.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/9779704/pubmed" id="9779704" target="_blank">9779704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8164044">
<a name="8164044"></a>Pein F, Tournade MF, Zucker JM, et al. Etoposide and carboplatin: a highly effective combination in relapsed or refractory Wilms' tumor--a phase II study by the French Society of Pediatric Oncology. <i>J Clin Oncol.</i> 1994;12(5):931-936.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/8164044/pubmed" id="8164044" target="_blank">8164044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10618614">
<a name="10618614"></a>Perez EA, Hillman DW, Stella PJ, et al. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. <i>Cancer</i>. 2000;88(1):124-131. doi:10.1002/(sici)1097-0142(20000101)88:1&lt;124::aid-cncr17&gt;3.3.co;2-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/10618614/pubmed" id="10618614" target="_blank">10618614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32305099">
<a name="32305099"></a>Pfisterer J, Shannon CM, Baumann K, et al; AGO-OVAR 2.21/ENGOT-ov 18 Investigators. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. <i>Lancet Oncol.</i> 2020;21(5):699-709. doi:10.1016/S1470-2045(20)30142-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/32305099/pubmed" id="32305099" target="_blank">32305099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24582486">
<a name="24582486"></a>Pignata S, Scambia G, Katsaros D, et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomized, multicenter, open-label, phase 3 trial. <i>Lancet Oncol.</i> 2014;15(4):396-405.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/24582486/pubmed" id="24582486" target="_blank">24582486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17960013">
<a name="17960013"></a>Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.<i> N Engl J Med.</i> 2007;357(17):1705-1715.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/17960013/pubmed" id="17960013" target="_blank">17960013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14645427">
<a name="14645427"></a>Poulsen M, Rischin D, Walpole, et al. High-Risk Merkel Cell Carcinoma of the Skin Treated With Synchronous Carboplatin/Etoposide and Radiation: A Trans-Tasman Radiation Oncology Group Study --TROG 96:07. <i>J Clin Oncol.</i> 2003;21(23):4371-4376.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/14645427/pubmed" id="14645427" target="_blank">14645427</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18707820">
<a name="18707820"></a>Poulsen M, Walpole E, Harvey J, et al. Weekly Carboplatin Reduces Toxicity During Synchronous Chemoradiotherapy for Merkel Cell Carcinoma of Skin. <i>Int J Radiat Oncol Biol Phys.</i> 2008;72(4):1070-1074.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/18707820/pubmed" id="18707820" target="_blank">18707820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32945632">
<a name="32945632"></a>Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. <i>N Engl J Med</i>. 2020;383(13):1218-1230. doi:10.1056/NEJMoa2002788<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/32945632/pubmed" id="32945632" target="_blank">32945632</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20498395">
<a name="20498395"></a>Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. <i>J Clin Oncol</i>. 2010;28(20):3323-3329. doi:10.1200/JCO.2009.25.7519<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/20498395/pubmed" id="20498395" target="_blank">20498395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22370329">
<a name="22370329"></a>Qaddoumi I, Bass JK, Wu J, et al. Carboplatin-Associated Ototoxicity in Children With Retinoblastoma. <i>J Clin Oncol.</i> 2012;30(10):1034-1041.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/22370329/pubmed" id="22370329" target="_blank">22370329</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18512224">
<a name="18512224"></a>Ramalingam S, Perry MC, La Rocca RV, et al. Comparison of Outcomes for Elderly Patients Treated With Weekly Paclitaxel in Combination With Carboplatin versus the Standard 3-Weekly Paclitaxel and Carboplatin for Advanced Nonsmall Cell Lung Cancer. <i>Cancer. </i>2008;113(3):542-546.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/18512224/pubmed" id="18512224" target="_blank">18512224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16342250">
<a name="16342250"></a>Rao D, Holtan SG, Ingle JN, et al. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. <i>Cancer.</i> 2006;106(2):375-382.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/16342250/pubmed" id="16342250" target="_blank">16342250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32530769">
<a name="32530769"></a>Rao S, Sclafani F, Eng C, et al. International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: InterAAct. <i>J Clin Oncol</i>. 2020;38(22):2510-2518. doi:10.1200/JCO.19.03266<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/32530769/pubmed" id="32530769" target="_blank">32530769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26401644">
<a name="26401644"></a>Rathod PS, Kundargi R, Pallavi VR, et al. Refractory gestational trophoblastic neoplasia: a novel drug combination with paclitaxel and carboplatin produces durable complete remission. <i>Int J Gynecol Cancer</i>. 2015;25(9):1737-1741. doi:10.1097/IGC.000000000000055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/26401644/pubmed" id="26401644" target="_blank">26401644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32763109">
<a name="32763109"></a>Redondo A, Colombo N, McCormack M, et al. Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer. <i>Gynecol Oncol</i>. 2020;159(1):142-149. doi:10.1016/j.ygyno.2020.07.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/32763109/pubmed" id="32763109" target="_blank">32763109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16782917">
<a name="16782917"></a>Robert N, Leyland-Jones B, Asmar L, et al. Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2-Overexpressing Metastatic Breast Cancer. <i>J Clin Oncol.</i> 2006;24(18):2786-2792.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/16782917/pubmed" id="16782917" target="_blank">16782917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12743157">
<a name="12743157"></a>Rodriguez-Galindo C, Wilson MW, Haik BG, et al. Treatment of Intraocular Retinoblastoma With Vincristine and Carboplatin. <i>J Clin Oncol.</i> 2003;21(10):2019-2025.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/12743157/pubmed" id="12743157" target="_blank">12743157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20555089">
<a name="20555089"></a>Roila F, Herrstedt J, Aapro M, et al; ESMO/MASCC Guidelines Working Group. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. <i>Ann Oncol</i>. 2010;21(suppl 5):v232-v243.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/20555089/pubmed" id="20555089" target="_blank">20555089</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27664248">
<a name="27664248"></a>Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/27664248/pubmed" id="27664248" target="_blank">27664248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9649151">
<a name="9649151"></a>Rubie H, Michon J, Plantaz D, et al. Unresectable Localized Neuroblastoma: Improved Survival After Primary Chemotherapy Including Carboplatin-Etoposide. Neuroblastoma Study Group of the Societe Francaise d'Oncologie Pediatrique (SFOP). <i>Br J Cancer.</i> 1998;77(12):2310-2317.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/9649151/pubmed" id="9649151" target="_blank">9649151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11464897">
<a name="11464897"></a>Rubie H, Plantaz D, Coze C, et al. Localised and unresectable neuroblastoma in infants: excellent outcome with primary chemotherapy. neuroblastoma study group, Société Française d'Oncologie Pédiatrique. <i>Med Pediatr Oncol.</i> 2001;36(1):247-250.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/11464897/pubmed" id="11464897" target="_blank">11464897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26351333">
<a name="26351333"></a>Rudin CM, Ismaila N, Hann CL, et al. Treatment of small-cell lung cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. <i>J Clin Oncol</i>. 2015;33(34):4106-4111.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/26351333/pubmed" id="26351333" target="_blank">26351333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26351333">
<a name="26351333"></a>Sandhu G, Adattini J, Armstrong Gordon E, O’Neill N; ADDIKD Guideline Working Group. International consensus guideline on anticancer drug dosing in kidney dysfunction. 2022. eviQ, Cancer Institute NSW. St. Leonards, Australia. https://www.eviq.org.au/clinical-resources/addikd-guideline/4174-anticancer-drug-dosing-in-kidney-dysfunction.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/26351333/pubmed" id="26351333" target="_blank">26351333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17167137">
<a name="17167137"></a>Sandler A, Gray R, Perry MC, et al. Paclitaxel-Carboplatin Alone or With Bevacizumab for Non-Small-Cell Lung Cancer. <i>N Engl J Med.</i> 2006;355(24):2542-2550.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/17167137/pubmed" id="17167137" target="_blank">17167137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18594322">
<a name="18594322"></a>Santoro A, O'Brien ME, Stahel RA, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. <i>J Thorac Oncol</i>. 2008;3(7):756-763. doi:10.1097/JTO.0b013e31817c73d6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/18594322/pubmed" id="18594322" target="_blank">18594322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28342551">
<a name="28342551"></a>Santos-Bueso E, Muñoz-Hernández AM, Porta-Etessam J, Benítez-Del-Castillo JM. Bilateral haemorrhagic papilloedema secondary to carboplatin use. Edema de papila bilateral hemorrágico secundario a carboplatino. <i>Neurologia (Engl Ed)</i>. 2019;34(9):614-616. doi:10.1016/j.nrl.2017.01.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/28342551/pubmed" id="28342551" target="_blank">28342551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35139274">
<a name="35139274"></a>Schmid P, Cortes J, Dent R, et al; KEYNOTE-522 Investigators. Event-free survival with pembrolizumab in early triple-negative breast cancer. <i>N Engl J Med</i>. 2022;386(6):556-567. doi:10.1056/NEJMoa2112651<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/35139274/pubmed" id="35139274" target="_blank">35139274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32101663">
<a name="32101663"></a>Schmid P, Cortes J, Pusztai L, et al; KEYNOTE-522 Investigators. Pembrolizumab for early triple-negative breast cancer. <i>N Engl J Med</i>. 2020;382(9):810-821. doi:10.1056/NEJMoa1910549<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/32101663/pubmed" id="32101663" target="_blank">32101663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16423848">
<a name="16423848"></a>Schmittel A, Fischer von Weikersthal L, Sebastian M, et al. A Randomized Phase II Trial of Irinotecan Plus Carboplatin Versus Etoposide Plus Carboplatin Treatment in Patients With Extended Disease Small-Cell Lung Cancer. <i>Ann Oncol.</i> 2006;17(4):663-667.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/16423848/pubmed" id="16423848" target="_blank">16423848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23704196">
<a name="23704196"></a>Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). <i>Ann Oncol</i>. 2013;24(9):2278-2284. doi:10.1093/annonc/mdt182<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/23704196/pubmed" id="23704196" target="_blank">23704196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17380438">
<a name="17380438"></a>Secord AA, Havrilesky LJ, Carney ME, et al. Weekly Low-Dose Paclitaxel and Carboplatin in the Treatment of Advanced or Recurrent Cervical and Endometrial Cancer. <i>Int J Clin Oncol. </i>2007;12(1):31-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/17380438/pubmed" id="17380438" target="_blank">17380438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27301700">
<a name="27301700"></a>Sharma P, López-Tarruella S, García-Saenz JA, et al. Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: combined analysis of two cohorts. <i>Clin Cancer Res</i>. 2017;23(3):649-657. doi:10.1158/1078-0432.CCR-16-0162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/27301700/pubmed" id="27301700" target="_blank">27301700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30061361">
<a name="30061361"></a>Sharma P, López-Tarruella S, García-Saenz JA, et al. Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel. <i>Clin Cancer Res</i>. 2018;24(23):5820-5829. doi:10.1158/1078-0432.CCR-18-0585<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/30061361/pubmed" id="30061361" target="_blank">30061361</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11697833">
<a name="11697833"></a>Skarlos DV, Samantas E, Briassoulis E, et al. Randomized Comparison of Early Versus Late Hyperfractionated Thoracic Irradiation Concurrently With Chemotherapy in Limited Disease Small-Cell Lung Cancer: A Randomized Phase II Study of the Hellenic Cooperative Oncology Group (HeCOG). <i>Ann Oncol.</i> 2001;12(9):1231-1238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/11697833/pubmed" id="11697833" target="_blank">11697833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21991949">
<a name="21991949"></a>Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. <i>N Engl J Med</i>. 2011;365(14):1273-1283. doi:10.1056/NEJMoa0910383<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/21991949/pubmed" id="21991949" target="_blank">21991949</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23130564">
<a name="23130564"></a>Smallridge RC, Ain KB, Asa SL, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. <i>Thyroid.</i> 2012;22(11):1104-39.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/23130564/pubmed" id="23130564" target="_blank">23130564</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22547591">
<a name="22547591"></a>Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. <i>J Clin Oncol</i>. 2012;30(17):2055-2062. doi:10.1200/JCO.2011.39.5848<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/22547591/pubmed" id="22547591" target="_blank">22547591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29863955">
<a name="29863955"></a>Socinski MA, Jotte RM, Cappuzzo F, et al; IMpower150 Study Group. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. <i>N Engl J Med</i>. 2018;378(24):2288-2301. doi:10.1056/NEJMoa1716948<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/29863955/pubmed" id="29863955" target="_blank">29863955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19720897">
<a name="19720897"></a>Socinski MA, Smit EF, Lorigan P, et al. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. <i>J Clin Oncol</i>. 2009;27(28):4787-4792. doi:10.1200/JCO.2009.23.1548<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/19720897/pubmed" id="19720897" target="_blank">19720897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22967994">
<a name="22967994"></a>Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. <i>Ann Oncol.</i> 2013;24(1):152-160.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/22967994/pubmed" id="22967994" target="_blank">22967994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23721245">
<a name="23721245"></a>Sosa JA, Elisei R, Jarzab B, et al. Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. <i>Thyroid</i>. 2014;24(2):232-240.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/23721245/pubmed" id="23721245" target="_blank">23721245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18293386">
<a name="18293386"></a>Spreafico F, Bisogno G, Collini P, et al. Treatment of high-risk relapsed Wilms tumor with dose-intensive chemotherapy, marrow-ablative chemotherapy, and autologous hematopoietic stem cell support: experience by the Italian Association of Pediatric Hematology and Oncology. <i>Pediatr Blood Cancer</i>. 2008;51(1):23-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/18293386/pubmed" id="18293386" target="_blank">18293386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18809614">
<a name="18809614"></a>Strauss GM, Herndon JE 2nd, Maddaus AA, et al. Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non-Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. <i>J Clin Oncol.</i> 2008;26(31):5043-5051.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/18809614/pubmed" id="18809614" target="_blank">18809614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31059667">
<a name="31059667"></a>Stephenson A, Eggener SE, Bass EB, et al. Diagnosis and treatment of early stage testicular cancer: AUA guideline. <i>J Urol</i>. 2019;202(2):272-281. doi:10.1097/JU.0000000000000318<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/31059667/pubmed" id="31059667" target="_blank">31059667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20664477">
<a name="20664477"></a>Strosberg JR, Coppola D, Klimstra DS, et al. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. <i>Pancreas</i>. 2010;39(6):799-800.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/20664477/pubmed" id="20664477" target="_blank">20664477</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12860801">
<a name="12860801"></a>Sussman DA, Escalona-Benz E, Benz MS, et al. Comparison of Retinoblastoma Reduction for Chemotherapy vs External Beam Radiotherapy. <i>Arch Ophthalmol.</i> 2003;121(7):979-984.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/12860801/pubmed" id="12860801" target="_blank">12860801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15904950">
<a name="15904950"></a>Tinker AV, Bhagat K, Swenerton KD, et al. Carboplatin and Paclitaxel for Advanced and Recurrent Cervical Carcinoma: The British Columbia Cancer Agency Experience. <i>Gynecol Oncol.</i> 2005;98(1):54-58.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/15904950/pubmed" id="15904950" target="_blank">15904950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33297846">
<a name="33297846"></a>Tsang C, Akbari A, Frechette D, Brown PA. Accurate determination of glomerular filtration rate in adults for carboplatin dosing: moving beyond Cockcroft and Gault. <i>J Oncol Pharm Pract</i>. 2021;27(2):368-375. doi:10.1177/1078155220978446<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/33297846/pubmed" id="33297846" target="_blank">33297846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29713086">
<a name="29713086"></a>Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial. <i>Nat Med</i>. 2018;24(5):628-637. doi:10.1038/s41591-018-0009-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/29713086/pubmed" id="29713086" target="_blank">29713086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21115860">
<a name="21115860"></a>Valero V, Forbes J, Pegram MD, et al. Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab as First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens. <i>J Clin Oncol.</i> 2011;29(2):149-156.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/21115860/pubmed" id="21115860" target="_blank">21115860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1760899">
<a name="1760899"></a>van der Vijgh WJ. Clinical pharmacokinetics of carboplatin. <i>Clin Pharmacokinet</i>. 1991;21(4):242-261. doi:10.2165/00003088-199121040-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/1760899/pubmed" id="1760899" target="_blank">1760899</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22646630">
<a name="22646630"></a>Van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. <i>N Engl J Med.</i> 2012;366(22):2074-2084.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/22646630/pubmed" id="22646630" target="_blank">22646630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16670722">
<a name="16670722"></a>van Meerten E, Muller K, Tilanus HW, et al. Neoadjuvant Concurrent Chemoradiation With Weekly Paclitaxel and Carboplatin for Patients With Oesophageal Cancer: A Phase II Study. <i>Br J Cancer.</i> 2006;94(10):1389-1394.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/16670722/pubmed" id="16670722" target="_blank">16670722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15503297">
<a name="15503297"></a>van Winkle P, Angiolillo A, Krailo M, et al. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. <i>Pediatr Blood Cancer.</i> 2005;44(4):338-347. doi: 10.1002/pbc.20227.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/15503297/pubmed" id="15503297" target="_blank">15503297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15547181">
<a name="15547181"></a>Vasey PA, Jayson GC, Gordon A, et al. Phase III Randomized Trial of Docetaxel-Carboplatin Versus Paclitaxel-Carboplatin as First-Line Chemotherapy for Ovarian Carcinoma. <i>J Natl Cancer Inst.</i> 2004;96(22):1682-1691.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/15547181/pubmed" id="15547181" target="_blank">15547181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12209686">
<a name="12209686"></a>Vaughn DJ, Manola J, Dreicer R, et al. Phase II Study of Paclitaxel Plus Carboplatin in Patients With Advanced Carcinoma of the Urothelium and Renal Dysfunction (E2896): A Trial of the Eastern Cooperative Oncology Group. <i>Cancer.</i> 2002;95(5):1022-1027.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/12209686/pubmed" id="12209686" target="_blank">12209686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30413383">
<a name="30413383"></a>Vergote I, Coens C, Nankivell M, et al; EORTC; MRC CHORUS study investigators. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials [published correction appears in <i>Lancet Oncol</i>. 2019;20(1):e10]. <i>Lancet Oncol</i>. 2018;19(12):1680-1687. doi: 10.1016/S1470-2045(18)30566-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/30413383/pubmed" id="30413383" target="_blank">30413383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20818904">
<a name="20818904"></a>Vergote I, Tropé CG, Amant F, et al; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. <i>N Engl J Med</i>. 2010;363(10):943-53. doi: 10.1056/NEJMoa0908806.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/20818904/pubmed" id="20818904" target="_blank">20818904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18784101">
<a name="18784101"></a>Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. <i>N Engl J Med. </i>2008;359(11):1116-1127.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/18784101/pubmed" id="18784101" target="_blank">18784101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11812097">
<a name="11812097"></a>Watanabe M, Aoki Y, Tomita M, et al. Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer. <i>Gynecol Oncol</i>. 2002;84(2):335-338. doi:10.1006/gyno.2001.6527<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/11812097/pubmed" id="11812097" target="_blank">11812097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2258080">
<a name="2258080"></a>Weiss GR, Green S, Hannigan EV, et al. A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study. <i>Gynecol Oncol.</i> 1990;39(3):332-336.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/2258080/pubmed" id="2258080" target="_blank">2258080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31122901">
<a name="31122901"></a>West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (Impower130): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncol</i>. 2019;20(7):924-937. doi:10.1016/S1470-2045(19)30167-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/31122901/pubmed" id="31122901" target="_blank">31122901</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15581952">
<a name="15581952"></a>Williams SD, Kauderer J, Burnett AF, et al. Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group. <i>Gynecol Oncol.</i> 2004;95(3):496-499.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/15581952/pubmed" id="15581952" target="_blank">15581952</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27502591">
<a name="27502591"></a>Wright AA, Bohlke K, Armstrong DK, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2016;34(28):3460-3473. doi: 10.1200/JCO.2016.68.6907.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/27502591/pubmed" id="27502591" target="_blank">27502591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29878040">
<a name="29878040"></a>Yardley DA, Coleman R, Conte P, et al; tnAcity investigators. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. <i>Ann Oncol</i>. 2018;29(8):1763-1770. doi:10.1093/annonc/mdy201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/29878040/pubmed" id="29878040" target="_blank">29878040</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19088717">
<a name="19088717"></a>Yonemori K, Ando M, Yunokawa M, et al. Irinotecan plus carboplatin for patients with carcinoma of unknown primary site. <i>Br J Cancer.</i> 2009;100(1):50-55. doi:10.1038/sj.bjc.6604829<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/19088717/pubmed" id="19088717" target="_blank">19088717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1985722">
<a name="1985722"></a>Zeltzer PM, Epport K, Nelson MD Jr, et al. Prolonged response to carboplatin in an infant with brain stem glioma. <i>Cancer.</i> 1991;67(1):43-f7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/carboplatin-pediatric-drug-information/abstract-text/1985722/pubmed" id="1985722" target="_blank">1985722</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13117 Version 411.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
